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Abstract 
 
 
Myocardial infarction (MI), more commonly known as a heart attack, affects 
millions of people every year. Infarcted heart tissue quickly undergoes necrosis, leaving 
the patient with portions of dead heart tissue that cannot function to efficiently pump 
blood throughout the body. Treatments involving resectioning of the heart muscle only 
restore form and not function. Other treatments and medications only treat the 
symptoms of MI and do not address the problem of dead tissue. Cell-based therapies 
are being pursued in an attempt to grow cardiac myocytes to replace the dead tissue 
within the heart. The purpose of this project was to develop a system to co-culture 
mouse cardiac myocytes with human mesenchymal stem cells with the goal of 
promoting the cardiac myocytes to express cell cycle markers, an indication of 
proliferative potential in cells. 
The team began by developing an agarose barrier that would maintain two 
separate populations of cells that could remain pure, while still being cultured in the 
same dish. Results showed that the agarose barrier was effective in preventing cell 
migration while still allowing media exchange. The team also developed a staining 
protocol for cyclin D1, a marker expressed during the cell cycle. Additionally, the team 
was able to stain control tissue for α-actinin, a marker found in cardiac cells. These 
finding suggest that this agarose barrier co-culture system can be used to co-culture 
cardiac myocytes with human mesenchymal stem cells in order to promote the 
myocytes to reenter the cell cycle, and potentially undergo mitosis. These cells could 
one day be used to regenerate functional myocardium in MI patients.   
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Executive Summary 
 
Myocardial infarction is a significant problem that affects almost 8 million people 
in the United States today. During myocardial infarction, also known as a heart attack, 
the myocytes that compose the heart are deprived of oxygen. This may lead to necrosis 
(cell death) and scar formation in the infarcted region, and decreased functionality of the 
heart.   
There are several methods that have been used to treat patients after myocardial 
infarction. Some treatments involve the removal or repositioning of the infracted tissue 
with ventricular resection or ventricular overlap surgeries. Other treatments involve 
replacing the damaged tissue with a patch of synthetic material designed to restore 
structure to the infarcted area. However, one common problem exists with these 
procedures: although the form of the tissue may be restored, functionality of the 
infarcted area is not recovered. This highlights the need for a treatment that can restore 
form and function to the damaged area.  
One alternate strategy for treating myocardial infarction is to replace the dead 
tissue with viable cells that will proliferate and restore complete functionality to the 
muscle. Some cell therapies involve directly injecting stem cells into the infarcted region 
with the intention that the stem cells will proliferate and differentiate into myocytes, 
eventually replacing the infarcted tissue. Another idea in cell therapy is to use stem cells 
to promote cardiac myocytes to proliferate. 
The proliferation of cardiac myocytes has been thought impossible until recently 
as new research has shown evidence of adult cardiomyocyte proliferation. By using 
stem cells to promote proliferation of existing cardiomyocytes, a sample of the patient’s 
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own cells could be used to produce a therapy that would both restore functionality to the 
damaged tissue within the heart, while also eliminating the possibility of rejection from 
donor cells. Additionally, the cardiomyocytes would be able to replace the damaged 
tissue without the need to introduce foreign stem cells into the patient, as the stem cells 
may not always follow a desired path of differentiation to become a cardiac myocyte.  
The goal of this project was to develop a design that separates cardiac myocytes 
from stem cells, while still allowing the two cell types to remain in a co-culture 
environment. To begin the project, the team completed background research in order to 
gain a greater understanding of the problem as well as research to date that has been 
completed by other research groups. Background research consisted of several main 
areas, namely the effects of myocardial infarction, the structure and function of cardiac 
myocytes, current approaches for cardiomyocyte regeneration research, and general 
cell culture techniques. This background aided the team in gaining a greater 
understanding of the current methods for culturing cells and conducting experiments 
related to cardiac myocyte regeneration.  
 Following the background, the team began to approach the project utilizing the 
process learned in the junior-level biomedical engineering design class. This included 
interviewing clients, developing an objectives tree, analyzing client-determined pairwise 
comparison charts, and developing a weighted objectives tree. The team successfully 
completed design matrices to determine the best methods for animal model choice, cell 
isolation procedures, media choice, and cell culture system design. The team also 
completed conceptual designs and moved on to the development of a preliminary 
design.  
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 The team pursued several designs during the project. After several unsuccessful 
attempts, the team finally developed a method to produce an agarose-based cell 
separation system. This system involves the use of a small agarose line placed on a 
cover slip in a Petri dish. The agarose, which is not harmful to cells, allows media to 
pass over the barrier in order to be exchanged between the two cell types, while 
preventing cells from migrating from one side of the dish to the other. Primary isolations 
were performed to acquire mouse cardiac myocytes from adult CF-1 mice, and human 
mesenchymal stem cells were obtained from the Gaudette lab. The two cell types were 
cultured on opposite sides of the agarose barrier and allowed to grow in co-culture for 
one week.  
 Results from the control studies showed positive results. The control migration 
study indicated that the mesenchymal stem cells were unable to migrate past the 
agarose barrier after 10 days in culture. Additionally, the team successfully isolated 
cardiac myocytes from adult mouse hearts. The team developed an analysis procedure 
to assess the effectiveness of the system as well. By developing a staining protocol for 
cyclin D1, a marker found in cells during the cell cycle, the team identified cells that 
have re-entered the cell cycle. Additionally, the team was able to modify an existing 
protocol for α-actinin stain. This staining protocol allows for the identification of cells that 
express characteristic striations found in cardiac tissue.  
 The team was able to develop a barrier system that is effective for separating cell 
populations while still allowing media exchange. Additionally, the staining protocols for 
cyclin D1 and α-actinin demonstrate the ability to analyze the system’s effectiveness in 
the future. However, the team was unsuccessful in gathering data that confirmed 
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myocyte cell cycle reentry using the co-culture system for several possible reasons 
including enzyme batch changes and high passage number stem cells. 
 In the future, there are several modifications that can be made to this project in 
order to improve the system. By reducing the size of the system to a 12-well or 24-well 
plate, more cells can be cultured at one time, possibly producing better results. Media 
and serum formulations should also be re-evaluated in order to find the most effective 
combination for this system. Finally, using human heart cells in this system would be the 
ultimate goal, as human cells would be necessary for treatment of human MI. The team 
believes that ultimately this system can be used for two purposes. First, the system can 
be used as a research tool to identify the specific paracrine factors secreted from the 
stem cells that promote cardiac myocytes to re-enter the cell cycle. Second, this system 
can be used to develop a population of cardiac myocytes that can undergo mitosis. 
Once a sufficient number of myocytes has regenerated, they can be delivered to the 
heart to regenerate the damaged myocardium. Overall, the team believes that this 
system has great potential for future treatment of damaged myocardium caused by 
myocardial infarction.  
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1. Introduction  
 
Myocardial infarction (MI) affects 7.9 million people in the United States today 
(Rosamond, 2007). During an MI, more commonly known as a heart attack, a section of 
the tissue within the heart is deprived of oxygen for an extended period of time due to a 
blockage in one or more coronary blood vessels. This leads to necrosis, or death of the 
surrounding tissue, which is made of myocytes. As the myocytes die the functionality of 
the heart decreases, leaving the patient with a damaged heart that can no longer 
function as well as before the MI. This causes the heart to do more work in order to 
keep the patient alive which increases the stress on the heart muscle itself. There are 
other functional problems such as decreased stroke volume which leads to a decrease 
in the oxygenated blood being delivered to the rest of the body. The damaged tissue 
may also lose mechanical integrity, leading to a ventricular aneurism. These factors are 
often detrimental to patient’s health (Rosamond, 2007).  
There are several different therapies that are used to treat patients with infarcted 
heart tissue. These therapies can include several variations of geometrical remodeling 
via surgery. The endoventricular patch plasty (Dor procedure), septal anterior 
ventricular exclusion (SAVE), and overlapping procedures are all performed to change 
the form of the heart in the attempt to strengthen the damaged muscle in order to avoid 
future problems with aneurism (Ueno et al., 2007). Many surgeons will also perform 
some sort of revascularization such as a vessel bypass graft in order to restore blood 
flow to the infarcted area (Bockeria, et al., 2006). Although these procedures try to 
restore the macroscopic form of the heart, they lack the ability to restore function to the 
infarcted tissue. This leaves the patient with the problem of reduced general heart 
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function and most likely a reduced ability to perform normal daily functions as compared 
to what the patient would have experienced before the myocardial infarction. 
There is a specific need for a post-MI treatment that will restore both form and 
function to the damaged heart tissue. One of the newer treatments being investigated 
involves the use of cell therapy to repair the damaged heart tissue. One form of cell 
therapy involves direct injection of stem cells into the necrotic tissue with the intention 
that the stem cells will proliferate and differentiate into functioning cardiac myocytes 
(Collins et al., 2007). However, there is no guarantee that the stem cells will all 
differentiate into cardiac myocytes, and therefore no assurance that complete 
restoration of the tissue will occur. Research has been conducted to indicate that there 
is a small population of cardiac stem cells within the human heart, along with a small 
population of myocytes that can re-enter the cell cycle and proliferate after a traumatic 
cardiac event (Anversa, 1998). However these myocytes cannot regenerate enough 
tissue to repair the infracted region, so the affected tissue cannot be replaced and the 
heart remains injured. The purpose of this project was to investigate the process of co-
culturing cardiac myocytes with human mesenchymal stem cells with the goal of 
increasing cell cycle markers in cardiac myocytes in vitro. The increase of cell cycle 
markers indicates the possibility of stimulating cells to re-enter the cell cycle and to 
undergo mitosis to proliferate. We anticipated that this in vitro culture technique could 
be used as a protocol for culturing a physiologically significant number of cardiac 
myocytes to deliver to infracted heart tissue to regenerate the infracted region of the 
heart.  
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The team’s efforts consisted of a process of engineering design based on the 
techniques learned in the junior level design class. Matrices were used to analyze 
various design ideas for their functionality and cost effectiveness. After completing 
several design analyses, the team pursued several designs in the lab in order to 
discover the most effective design.  
The final design provided a co-culture system suitable for the desired results: 
compatibility with cell culture (i.e. does not harm cells) while providing an effective co-
culture system in which the cells can exchange media while retaining separate 
populations. Control studies were conducted to prove that the system can effectively 
retain two separated cell populations for at least one week. The team also developed an 
analysis procedure that can be used to identify cells that have re-entered the cell cycle. 
This procedure could also be used to identify cardiac myocytes that have retained 
striation, a characteristic of cardiac cells. The design was ultimately used to co-culture 
cardiac myocytes with human mesenchymal stem cells in the attempt to promote 
cardiomyocytes to produce cell cycle markers, an indicator of the potential for mitosis in 
living cells.  
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2. Literature Review 
In order to be able to design a system that will allow for the successful increase 
of cell cycle markers in adult cardiac myocytes, it was necessary to perform a review of 
relevant literature. The following is a review of the areas of myocardial infarction, 
cardiac myocytes, current approaches to treating myocardial infarction, and cell culture 
techniques.  
2.1 Myocardial Infarction 
Myocardial infarction (MI) is a major health problem in all areas of the world. 
According to the American Heart Association (AHA), almost 8 million Americans are 
affected by MI (Rosamond, 2007). The Joint European Society of Cardiology/American 
College of Cardiology Committee defines MI as a condition involving myocardial 
necrosis, or the death of heart tissue. Depending on the severity of the MI, up to one 
third of the cardiac myocytes in the left ventricle can die (MI Redefined, 2000). Without 
these cardiac myocytes, which are the contractile cells in the heart, the functionality of 
the heart can drastically decrease. The AHA states that MI will cause death within five 
years for 33% of men and 43% of women over the age of 40. This decrease in heart 
function also may lead to heart failure in 5 years for 7% of men and 12% of women 
between the ages of 40 and 69. For patients age 70 and over, the chances of heart 
failure within 5 years raises to 22% of men and 25% of women (Rosamond, 2007). It is 
estimated that 30% of patients who experience heart failure will die within the first year 
(Engel, 2005). 
As these statistics suggest, there is no cure for myocardial necrosis. This is 
mainly because adult cardiac myocytes in humans do not proliferate (Ahuja, 2007). 
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Therefore, there is no mechanism in the human heart to regenerate the dead tissue 
following MI. Considerable research is ongoing in the biomedical field to find a way to 
promote cardiac myocyte proliferation. The intention of this research is to find a way to 
either induce the healthy myocytes to proliferate in vivo or to promote the cardiac 
myocytes to proliferate in vitro and use those cells to replace the dead cells in the heart.   
2.2 Cardiac Myocytes 
  In order to perform successful experiments with cardiac myocytes, it is important 
to understand the structure and function of the cells. The following is a review of the 
structure and function of cardiac myocytes and their life cycle.  
2.2.1 Structure and Function 
There are roughly 8 billion heart muscle cells, also known as myocytes, in the 
heart of a healthy adult human (Ford, 2000). Heart muscle cells are short in length as 
compared to other muscle cells in the body, and they also have projections that branch 
out from the cell.  The diameter of cardiac cells is usually around 5-15µm. The ends of 
myocytes are connected to each other via intercalated disks. The intercalated disks 
allow contractile forces and small molecules to flow from one cell through to another. 
Some cardiac cells have only one nucleus in the center, but some can be bi- or multi-
nucleated.  
The walls of the heart are formed by cells with connected channels called gap 
junctions that allow the flow of small molecules and ions between cells. The major 
function of these passages is to allow electric current carried by the ions in the cells to 
flow to adjacent cells, thereby propagating the electrical signal to produce a heartbeat. 
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The action potential of cardiac myocytes increases rapidly from -80mV to 40mV during 
contraction of the heart muscle. The action potentials then decrease slowly, during 
which time they cannot generate a full contractile response again until the cells 
repolarize. Once repolarization has occurred, the cell is ready to contract once again 
(Ford, 2000). 
2.2.2  Life Cycle 
 The life cycle of a human cardiac myocyte is much different than most other cells 
in the body. They are similar to other cells in that they proliferate via the cell cycle 
during fetal life, but that is where the similarities end. Adult cardiac myocytes do not 
proliferate on their own, where some other cells in the body replicate in order to replace 
old or damaged cells in the tissue or organ system such as skin. 
 During the rapid growth period in the fetus, embryonic cardiac myocytes 
proliferate quickly in order to maintain a steady growth rate with the rest of the body. In 
general, the cell cycle involves four phases. Cells perform basic functions during G1, S, 
and G2 phases. Mitosis occurs during M (mitosis) phase, producing two separate 
daughter cells from one parent cell. (Marieb and Hoehn, 2007).The cell cycle can be 
seen below in Figure 1.  
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Figure 1: The Typical Cell Cycle. 
The cell cycle of a cardiac myocyte is coordinated by various regulating proteins 
that are expressed in the cell at different stages of the cycle. As can be seen in 
Appendix A: Cell Cycle Regulator Proteins, these regulatory proteins can be divided into 
three groups: mediators, inhibitors, and transcription factors. Mediators aid the progress 
of the cell cycle, where inhibitors attempt to stop the cell cycle by deterring the function 
of the mediators. The transcription factors help with the transcription process of DNA 
(Ahuja, 2007).  
 Immediately after birth, cardiac myocytes still proliferate. After a few days, the 
cells exit the cell cycle and, until recently, it was believed that they did not begin to 
proliferate again. Some of the myocytes replicate DNA once more before exiting the cell 
cycle, but they do not undergo cytokinesis, which causes binucleation. It is estimated 
that 25 to 57% of adult cardiac myocytes are binucleated (Ahuja, 2007). As the infant 
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ages, the cells undergo hypertrophy, or growth within the cell, which causes the heart to 
grow to adult size. 
Until recently, it was assumed that there were no adult cardiac myocytes capable 
of re-entering the cell cycle. In a 2001 study published by doctors at New York Medical 
College, the University of Udine in Italy, and the University of Trieste in Italy, it was 
determined that there are myocytes that are actively involved in the cell cycle. In fact, 
they were able to show that out of the myocytes surrounding an infarcted area, up to 4% 
were expressing Ki-67, an indicator of cell proliferation. In the regions far from the 
infarcted region, up to 1% of the myocytes were expressing Ki-67. The evidence 
showing that more cells around the dead area in the heart were in the cell cycle than in 
the healthy tissue indicates that the cell death may spur the reentry into the cell cycle. 
This means that the heart may have some limited ability to regenerate to replace the 
dead tissue (Beltrami, 2001). However, even if this is the case, the heart would not be 
able to completely replace the dead tissue without additional help. It is on this 
hypothesis, that cell cycle reentry is possible, that most of the current research is based. 
2.3 Current Approaches  
 Based on the hypothesis that cardiac myocytes reenter the cell cycle, there are a 
number of research laboratories around the world trying to promote myocyte 
regeneration in human ventricular myocytes. The following is a review of relevant 
literature with respect to this problem, including reasons for why traditional treatments 
are not completely effective, research into embryonic myocyte development, stem cells 
and their effect on cardiac myocyte proliferation, and an overview of co-culture systems. 
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2.3.1 The Problem with Traditional Treatments 
Many traditional non-cell related treatments for post-MI patients involve trying to 
restore form rather than function to the affected myocardium. After a heart attack, the 
infarcted tissue in the heart is dead, and therefore can no longer function as healthy 
tissue. In some patients, the infarcted region loses mechanical integrity due to the 
reduction in healthy tissue. This causes the wall of the heart to expand in an aneurysm, 
a condition that can further reduce cardiac function if not treated (Ueno et al., 2007). In 
order to avoid this complication, traditional treatments were developed in the attempt to 
restore the form of the heart. 
There are several different treatments that can be used after MI to restore form to 
the heart. Ventricular patch plasty, also known as the Dor procedure, involves removing 
the infarcted tissue and sewing the remaining healthy tissue together (Bockeria et al., 
2006). Another procedure known as “septal anterior ventricular exclusion” (SAVE) 
involves the use of a synthetic patch to restore form to the heart, and is used when the 
septum is affected by ischemia (Isomura et al., 2006). The overlapping procedure is 
similar to the Dor procedure with the exception of leaving the infracted tissue in the 
heart, and overlapping / sewing together the healthy tissue to restore form (Matsui et al., 
2002). Some procedures also involve the use of revascularization techniques such as 
coronary artery bypass grafts (CABG) in order to restore blood flow to the tissue 
(Ribeiro et al., 2006, Bockeria et al., 2006). Although such a procedure would be 
beneficial to ischemic tissue, infarcted tissue cannot be restored to a living, functional 
state through revascularization because the tissue is already dead. Other treatments 
involve the use of medication and other therapies that treat the symptoms.  
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 The problem with the traditional treatments is that they only treat the symptoms, 
and some can only restore form to the heart, not function. By observing the structure of 
the heart muscle itself, it becomes clear that a procedure such as the Dor or SAVE does 
not yield the same heart function as was present before the infarct. For example, by 
studying the structure of the “helical ventricular myocardial band”, as discovered by 
Francisco Torrent-Guasp (Kocica et al., 2006), one can observe that cutting and re-
sectioning the tissue of the heart will alter the muscle structure, and therefore alter the 
form and function of the heart itself. Since none of these procedures can restore the 
functionality of the heart, it is important to research cell-based therapies that may be 
more effective in repairing myocardial tissue. 
2.3.2 Embryonic Cardiac Myocyte Development 
 Research has been conducted with embryonic cardiac myocytes and the specific 
roles of the regulatory proteins in myocyte development. One study in particular was 
published in 2007 by Ahuja, Sdek, and Maclellan. They suppressed or overexpressed 
certain regulatory proteins (see Appendix A: Cell Cycle Regulator Proteins) in 
embryonic mice and measured the difference in the heart weight to body weight ratios. 
As can be expected, the over-expression of mediator proteins and suppression of 
inhibitor proteins increased the heart weight, sometimes with drastic results. For 
example, mice suppressing developmental myocardial proteins such as Rb and p130 
increased their heart weight/body weight ratio 300% (Ahuja et al, 2007). 
 Although this is a proven method to proliferating myocytes, it would not be an 
acceptable means. There is much debate about the ethical issues surrounding the use 
of embryonic cells for research purposes, and these issues are outside of the scope of 
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this project. However, this research is useful in indicating that proteins have a significant 
influence on myocyte proliferation, and it may be worth investigating the effects of 
proteins on adult cardiac myocytes once a suitable co-culture system is devised. 
2.3.3 Stem Cells 
Stem cell research is a relatively new and controversial field of scientific research. 
There has been much hype surrounding stem cell research since it was first developed 
decades ago, as many people thought that stem cell research and tissue engineering 
would be the technologies that could cure all disease and ailments within the human 
body (Ingber and Levin, 2007). To that end, there has been much research conducted 
using different types of stem cells. One of the main types of research being conducted, 
and the type most relevant to this project, is using stem cells for organ and tissue 
regeneration, specifically cardiac regeneration. 
It is important to understand that there are two different types of stem cells: 
embryonic and adult. Embryos are the basis of all mammalian life. All of the tissues 
found within the mammalian body are products of embryonic growth due to the 
totipotent nature of embryonic stem cells. Totipotency is the ability of a cell to 
differentiate into any cell within the body. The goal of scientific stem cell research is to 
be able to grow any tissue, organ, or body part from the embryonic stem cells in order to 
cure diseases and replaced damaged tissues. Due to the controversy over the issue 
(Vats et al., 2005), and a limited cell supply, embryonic stem cells are not a viable 
option for this project.  
Another major type of stem cell is the adult stem cell. These cells are found within 
different regions of the body including the hippocampus region of the brain, bone 
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marrow within long bones, and within the heart, to name a few. Adult stem cells do not 
have the same totipotent nature as embryonic stem cells, but many do have the ability 
to differentiate into several different cell types. Many adult stem cells are actually 
progenitor cells, meaning that they have already begun to differentiate into one tissue 
type, but have not yet differentiated into a specific type of cell. One example of this is a 
neural progenitor cell, which can differentiate into neurons, oligodendrocytes, and 
astrocytes (Czyz et al, 2003).  
Until recently, organ and tissue transplants were the only way to treat many 
significantly damaged or diseased tissues while still allowing the patient to live a full and 
healthy life. There are two significant problems with organ and tissue transplants; the 
shortage of available tissue, and immune reactions from the patient’s body in response 
to the foreign tissue that is implanted. For these reasons, the ability to grow an organ or 
tissue in vitro would be extremely useful in the treatment of different diseases and tissue 
damaging conditions. Cell therapy involves the use of the patient’s own cells to grow a 
tissue or organ in vitro, and replace the damaged tissue with the healthy tissue once it 
has grown to its necessary size and functionality. In theory, this could potentially cure 
many diseases and life-threatening conditions, but it cannot be done yet (Vats et al, 
2005).  
The goal of the research presented here is to use a combination of myocytes and 
stem cells to produce a system that can promote cardiac myocytes to re-enter the cell 
cycle and proliferate in vitro. If this can be accomplished, then the cells may be 
effectively delivered into damaged heart tissue. It is hypothesized that these cells will 
direct myocardial regeneration and the heart may regain complete functionality after a 
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myocardial infarction or other cardiac event, allowing the patient to live a full and healthy 
life.  
In the past, it was believed that a heart responded to MI by cell hypertrophy, or 
causing the cells to grow in size without actually completing the cell cycle. However, 
recent research has shown the heart is an organ with a resident population of 
differentiating myocytes and stem cells within the tissue. In fact, research has shown 
that in heart transplants from a female donor into a male recipient, the heart contains 
cell that are positive for the Y-chromosome, proving that there are cells from the body 
that can promote cardiac myocyte growth (Beltrami et al., 2003).  According to some 
labs, cardiac stem cells can be identified by the presence of three different markers; c-
kit (stem cell factor receptor), MDR-1 (multi-drug resistance-1), and Sca-1 (stem cell 
antigen-1) (Barile et. al, 2007). According to Barile et al., these stem cells also show the 
presence of telomerase, which is only seen in cells that have the ability to complete 
cytokinesis, the final step of mitosis in which two cells are formed from one.  
There has been much research about the use of stem cells in culture with cardiac 
myocytes in the attempt to have the stem cells proliferate into cardiac myocytes. Tang 
and coworkers have shown an effective method of isolating Sca-1+ cells from the heart, 
promoting cell proliferation, and introducing the cells back into the heart. Promising 
results were seen as the cells were still present in the heart after one month, and had 
differentiated into viable heart cells (Tang et al., 2007).  Another study by Oh et al. 
showed similar results with Sca-1+ cells promoting myocardial regeneration in an 
infarcted heart. Also, the study showed that most of the newly proliferating cells were 
those that were removed, promoted to differentiate into cardiac myocytes in culture, and 
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reintroduced into the heart. The introduction of the Sca-1+ cells did not promote the 
existing myocardium to regenerate (Oh et al., 2003). 
 Stem cells that are positive for c-kit have been studied extensively by several 
groups. Beltrami et al. were able to isolate and proliferate c-kit+ cells in culture through 
P26 (passage 26). The cells also showed preliminary differentiation, although the 
phenotypic cell type was not the same as what is found in normal tissue. Also, positive 
results that led to favorable cardiac function were observed when the cells were 
delivered to the heart and allowed to grow in vivo (Beltrami et al., 2003).  
 Mesenchymal stem cells (MSCs) have also been investigated as possible 
cardiomyocyte replacements. Xu et al. demonstrated this by establishing a way to 
isolate the MSCs from surrounding tissue, and promote them to differentiate into 
cardiomyocyte-like cells. The research showed positive results in vitro as chemical and 
visual analysis showed that the cells were similar to normal cardiomyocytes in that they 
produced cardiac markers such as α-actinin and desmin which are found in healthy 
cardiac tissue (Xu et al., 2004). Other labs have proven the effectiveness of co-culturing 
myocytes with mesenchymal stem cells. Research comparing co-cultured myocytes and 
MSCs with MSCs grown with conditioned media showed that direct myocyte to MSC 
contact is necessary in order to promote the MSCs to differentiate into functional 
myocytes (Rangappa et al, 2003; Wang et al., 2006).  
2.4 Cell Culture and Analysis 
 In order to perform successful cell culture experimentation, it is important to 
understand some of the basic principles that are applied to cell culture experimentation 
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and technique. The following section describes cell culture technique and 
immunocytochemistry which are essential to the success of the project.  
2.4.1 Cell Culture 
Cell culture is the process of growing cells in vitro in an environment that is sterile 
and provides everything necessary to keep the cells alive. After the cells have been 
dissociated from the tissue, they are grown in culture dishes with medium. The medium 
contains all the ingredients necessary to keep the cells alive including carbohydrates 
and proteins. Most medium also contains at least one antibiotic additive to avoid 
contamination of the cells. There are also other ingredients that can be added such as 
fetal bovine serum and growth factors to further promote cell growth and proliferation.  
Serums are extracted from the blood of living animals, i.e. fetal bovine serum is 
extracted from fetal cows. The serum contains a mixture of ingredients normally found 
within the donor blood serum. Although some of the items in the serum are known, 
there are things in serum what have not yet been defined. Therefore, any experiment 
that uses serum introduces another variable, as serum can be slightly different from 
animal to animal and batch to batch. Furthermore, the use of serum is potentially 
problematic when experimental protocols are translated to clinical environments. 
Other ingredients can be added to medium to develop a substance that is useful 
for a particular experiment. For example, specific quantities and types of vitamins, 
growth factors, amino acids, antibiotics, and other ingredients can be added to media 
preparations. These ingredients are known and have little variability between batches. 
This type of medium is known as defined medium. Because serum is not fully defined, 
media with serum cannot be considered defined. Experiments with cardiomyocytes 
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typically use a medium consisting of Dulbecco’s Modified Eagle Medium (DMEM) + 1% 
penicillin/streptomycin cocktail to prevent contamination, and 5% fetal bovine serum 
(FBS) (Rangappa et al., 2003, Doronin (submitted)). 
Some cells are known as anchorage-dependent cells meaning that they must 
have a suitable surface to adhere to in order to proliferate. This surface is usually the 
cell culture dish or flask. Other cells are not anchor-dependent, and can simply survive 
in a suspension surrounded with essential media. Cells can also be maintained for long 
amounts of time, such as in a cell line. Although cells from a cell line were originally part 
of a living organism, they are grown continually in culture in order to maintain a constant 
viable cell source without having to sacrifice more animals each time an experiment is 
to be performed (Freshney, 1994).  Cells such as human mesenchymal stem cells 
should be maintained in a simple flask system, with regular medium changes and 
passaging procedures to maintain the cells and to have cells available when necessary 
for experiments.  
The culture techniques described above are usually used to maintain a particular 
cell line. Cardiac myocytes that are cultured alone will not proliferate, so a co-culture 
system must be utilized for promoting cell cycle markers in cardiac myocytes. The co-
culture will utilize different media and culture dishes, but more than one cell type will be 
cultured in one dish. The purpose of the co-culture is to observe the effects of one cell 
type on the outcome of another cell type.  
There are three types of co-culture to be discussed here: contact co-culture, 
insert co-culture, and conditioned media culture. A cartoon of each of the three types of 
co-culture can be seen in Figure 2.  
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Contact co-culture involves using two different cell types, such as myocytes and 
stem cells, and plating them together in the same culture dish (Wang, 2006). The cells 
are both plated on the same surface and in the same area, and there is no attempt to 
separate the two cell populations as the ”contact” indicates that the two cell types are in 
contact with each other. The cells are then treated like any other cell culture, being 
given media to keep them alive and allow proliferation.  
Insert co-culture involves the use of a well-shaped insert (i.e. Transwell, Corning 
Incorporated) which is placed into the culture dish. One type of cell is placed on the 
insert, while the other is placed on the surface of the cell culture dish (Mensink, 1998). 
Figure 2: Types of Co-culture 
Contact Co-culture 
Insert Co-culture 
Conditioned Media 
Media 
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The insert itself only allows soluble molecules to flow through, while the cells stay in the 
places where they were initially seeded. 
 The third culture type, conditioned media, involves separately culturing two 
different types of cells in different dishes while using the media from one cell type to 
“feed” the other cell type (Rangappa et al., 2003). This allows any soluble molecules 
given off from one cell to be received by the other cell with the conditioned media use, 
while not having the cells in the same culture dish. A study by Rangappa et al. showed 
the differences between cardiomyocyte and hMSC direct co-culture (two cell types 
plated together) and cardiomyocyte / hMSC conditioned media experiments. The focus 
of this experiment was to promote the hMSCs to differentiate into cardiomyocytes, and 
the results showed that direct cell-cell contact was necessary for this to occur. The 
conditioned media was less successful than the direct co-culture (Rangappa et al., 
2003). 
Co-culture systems are not limited to those listed previously. Other forms of co-
culture involve the use of a different system than those named above. This involves 
using some sort of new technique that allows two cells to be cultured in the same dish 
or well without the cells coming into contact. A system such as this would allow for 
media to be exchanged freely between cells.  The cells are also separated into two 
distinct areas and allowed to exist separately, which would allow for easy removal of 
one population if necessary. Depending on the system, cells may be allowed to grow 
close together (i.e. closer than a Transwell) while still remaining separated.  
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2.4.2 Immunocytochemistry 
 Immunocytochemistry is a technique that allows for visualization of specific 
antigens or proteins in cells. By using immunocytochemistry, the number of cells 
expressing the protein or presenting the antigen can be determined. Also, the 
placement of the antigen or protein in the cell can be determined. 
 The process of immunocytochemistry begins with applying a primary antibody 
that is specific to the antigen or protein of interest to the cell sample. In direct labeling, 
the primary antibody is labeled with a fluorescent marker that can be analyzed through 
microscopy. In indirect labeling, a fluorescent marked secondary antibody binds to the 
primary antibody and then the sample can be analyzed through microscopy (Principles 
and Techniques of Practical Biochemistry, 2000). This binding sequence is shown in 
Figure 3. 
 
Figure 3: Immunofluorescent Labeling 
For the purposes of this project, labels for proteins found during the cell cycle will 
be useful for visualizing cells that are undergoing mitosis. Ki-67 is a protein that has 
been used to identify whether or not a cell is or has recently been actively involved in 
the cell cycle. Ki-67 only appears during cell proliferation and is present during all active 
phases of cell cycles (G1, S, G2, and mitosis). It is absent from resting cells (G0). During 
interphase, the protein is exclusively detected in the nucleus. While in mitosis, the 
Cell 
Antigen 
Antigen specific 
primary antibody 
Fluorescence-tagged 
secondary antibody 
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protein relocates to the surface of the chromosomes. The monoclonal antibody used 
against the Ki-67 protein is MIB-1. MIB-1 overcomes the original Ki-67 antibody 
because it can be used in paraffin sections of tissues after antigen reassessment by 
microwave processing (Cattoretti et al., 1992). 
Another type of protein that can be found during the cell cycle is the cyclin 
protein. D-type cyclin proteins are responsible for initiating the response of cyclin-
dependent kinases (cdk) which are part of the cascading process for promoting the cell 
cycle to proceed. The cyclin/cdk combinations are important in every part of the cell 
cycle (Coqueret, 2002).  Cyclin D1 is a cyclin protein that identifies cells that are actively 
involved in the cell cycle, specifically in G1 phase (Kim et al., 2008).  More specifically, 
the cyclin D1 protein is present within the cell, but outside of the cell nucleus during G0, 
also known as the resting phase. As the cell prepares to enter the cell cycle, cyclin D1 
binds with cyclin dependent kinase 4 (CDK4), at which point the assembled product 
moves into the cell nucleus. While in the nucleus, the cyclin D1/CDK complex promotes 
a phosphorylation process that prompts the cell to progress through the G1 phase into 
the S phase (Gladden and Diehl, 2005). As discussed earlier, G1 involves centriole 
replication and prepares the cell for the cell cycle to continue. G1 occurs just before the 
S phase in which DNA is replicated, a key step in mitosis. As the cell moves into S 
phase, the cyclin D1/CDK4 complex relocates outside of the nucleus where the two 
parts separate and remain until the cell is prepared to enter the G1 phase again. 
Since cyclin D1 is expressed at the beginning of the cell cycle (G1), it can be 
used as a marker to detect cells that have recently moved out of the resting phase (G0) 
and begun to undergo the steps of the cell cycle. If a cell expresses cyclin D1, then 
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there is a high likelihood that the cell is progressing through the cell cycle. Because 
adult cardiomyocytes do not proceed through mitosis naturally, they do not naturally 
express cyclin D1. Therefore, a co-culture system that promoted cyclin D1 expression in 
cardiomyocytes would be successful in regards to promoting the cardiomyocytes to 
reenter the cell cycle.  
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3. Project Approach 
The literature review has provided a comprehensive overview of the past and 
current techniques and background information related to the problem.  This chapter 
summarizes the processes for developing a design, including hypothesis, assumptions, 
and specific aims.  
3.1 Hypothesis 
Currently, no methods exist to completely replace necrotic tissue of the heart 
after myocardial infarction.  Replacing this tissue is the only way to completely restore 
the functionality that is lost after an MI. Although a small population of proliferating 
myocytes does exist within the heart, these cells are not enough to repair the heart and 
replace the dead tissue.  We hypothesize that the presence of cell cycle markers can be 
increased in cardiac myocytes through the use of stem cell/cardiac myocyte co-culture. 
We believe that the stem cells release a paracrine factor that induces the myocytes to 
reenter the cell cycle, which is indicated by the cell cycle markers expressed in the co-
cultured myocytes.  If these myocytes can reenter the cell cycle and be induced to 
proliferate, the proliferating myocytes could be delivered to the post-MI heart and 
regenerate the necrotic tissue. This can only happen if the population of myocytes is a 
pure population, meaning that there cannot be any stem cells mixed into the myocytes 
that are delivered to the heart.  This is due to the fact that we are unsure of the effects 
of injecting stem cells into the cardiac tissue. However, if a pure population of 
proliferating myocytes can be produced, a potential treatment for MI can be developed.   
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3.2 Assumptions 
In order for any engineering project to be successful, it is important to define 
reasonable assumptions that will be used by the team during the design and 
experimental phase of the project.  The assumptions made by the project team are 
stated below: 
• Cells made to proliferate in vitro could be effectively delivered back into the heart 
without harming the cells. 
• Cells delivered into the heart would be able to integrate into the heart tissue to 
improve heart functionality by replacing necrotic tissue. 
• Newly proliferated cells have the same structural and biochemical properties of 
the native cardiac myocytes. 
3.3 Specific Aims 
In order to develop a solution to the problem presented, there are several specific 
aims that the team hopes to accomplish through the design and experimentation 
process: 
• Develop a system that can isolate living cardiac myocytes from the animal tissue 
so that cells can be used in cell culture 
• Develop a system that can be used to increase the presence of cell cycle 
markers in adult cardiac myocytes 
• Develop a system that will yield reproducible results 
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3.4 Project Specifications 
 
 To verify the success and effectiveness of the final design, the product must be 
designed to the following specifications: 
• The culturing system must co-culture myocytes with stem cells in an attempt to 
induce 5% more of the myocytes to express markers than myocytes that are not 
co-cultured. 
• There must be a barrier between the two different co-cultured populations that is 
at least 200 µm thick to prevent the stem cells from migrating into the myocyte 
population. 
• There must be a barrier between the two different co-cultured populations so the 
system will yield a myocyte population that is at least 90% pure. 
• The culturing system must take less than two weeks to produce results. 
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4. Design 
As with any engineering problem, there must be extensive thought and planning 
that goes into the design of the solution. By clarifying client needs, specifications, and 
constraints, it is possible to move forward through the design process to develop a 
suitable solution to the problem. 
4.1 Initial Problem Statement 
The problem initially presented to the project team consisted of the following: 
“Design a system or method that can effectively increase the presence of cell cycle 
markers in adult cardiac myocytes.” 
 In order to proceed in the design process, the problem statement needed to be 
expanded into the revised problem statement. This means that the team needed to 
identify the clients and users and discuss their needs and wants to complete the first 
step in the design process. 
4.1.1 Clarify Objectives 
 An important step in the design process is to identify the objectives that the 
design needs to fulfill. The best way of identifying these objectives is by discussing the 
design with the clients and the users of the design. In order to do this, the clients and 
users must be first identified.  Using the ideas presented in the design book written by 
Dym and Little in 2004, the team formed a designer-client-user triangle, as seen in  
Figure 4, to help visualize the relationship.  
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Figure 4: The designer-client-user triangle. (Dym, 2004) 
To help with the identification of these important parties, the team decided to 
define each role involved. The designer is the person or entity that will be developing 
the end product or methods. The client is the person or entity that presented the 
problem and is looking for a solution. The user is the person or entity that will be utilizing 
the end design in real world applications. Using these definitions, the team was able to 
identify the participants as shown in Figure 5. 
Designer
UserClient
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Figure 5: Identified designer-client-user triangle 
 After the designer-client-user relationship was established, the team developed a 
list of questions to understand the client and user wants and needs. These questions, 
with their answers, are provided in Appendix B: Interview with the Client and the User. 
Both clients in Figure 5 were interviewed and a Biomedical Engineering graduate 
student, Jacques Guyette, was interviewed as a user. From their answers to the 
questions the team was able to establish a list of objectives, constraints, and user 
requirements. The list of objectives can be seen in Table 1 below and the constraints 
and user requirements can be found in the next two sections. 
 
 
 
 
 
Designer:
MQP Team
User:
Professors, Students, 
Biomedical Companies, 
Clinicians
Client:
Professor Gaudette and 
Professor Pins
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Table 1: Design objectives 
Design Objectives 
Primary Objective Secondary Objective Tertiary Objective 
Express cell cycle markers 
Repeatable 
 Effective 
Safe 
For cells Non-toxic 
For users 
 
Efficient Minimize materials 
Media 
Cells 
Equipment 
Cost 
  
Ease of Use 
Interface 
 
Simplicity 
Time 
Size 
 
 From the list of objectives, the team created the objectives tree seen in Figure 6. 
This objective tree was approved by the client and allowed the team to make pairwise 
comparison charts, which are included in Appendix C: Pairwise Comparison Charts. 
These charts were sent to the client and user to be completed and sent back. The 
analyses of these charts, as seen in the Appendix, lead to the weighted objectives tree 
as seen in Figure 7.  The weights were determined by averaging the client and user 
weights for each objective.  These weights are used in the design process to determine 
which objectives are the most important to meet.  In the weighted objectives tree, the 
secondary and tertiary objectives have two weights.  The first is the percent of the 
above objective and the second is the weight overall. 
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Figure 6: Objectives Tree 
 
Figure 7: Weighted Objectives Tree 
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 The weighted objectives tree allows the team to prioritize the objectives.  The 
prioritized list of objectives can be seen below in Table 2. 
Table 2: Prioritized list of design objectives 
Design Objectives 
Primary Objective Secondary Objective Tertiary Objective 
33% Express cell cycle markers 
19.3% Effective 
 13.7% Repeatable 
23.5% Safe 
11.75% For cells 11.75% Non-toxic 
11.75% For users 
 
21.5% Efficient 21.5% Minimize materials 
9% Media 
7.2% Cells 
5.3% Equipment 
13% Cost 
  
9% Ease of Use 
2.7% Interface 
 
2.7% Simplicity 
2% Time 
1.6% Size 
 
 
 
4.1.2 Establish User Requirements 
 Based on the client and user interviews as described in the previous section, the 
team developed a list of user requirements as follows: 
• Must be able to fit into a cell culture hood and incubator 
• Must cost less than $100 per experiment 
• Must not use an excessive amount of resources 
• Must take 8 hours or less to prepare and produce results within 2 weeks 
• Must produce 5%-10% of cells expressing cell cycle markers 
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4.1.3 Identify Constraints 
Based on the client and user interviews, the team developed a list of design 
constraints: 
• Size: Must fit into a cell culture hood 
• Time: Must be able to complete culturing within two weeks. 
• Design Time: Prototype must be completed by April 1, 2008. 
• Cost: Prototype must cost less than the amount allotted by the Biomedical 
Engineering department, $468. 
• Sterile: Must provide a sterile environment for the cells to grow. 
• Migration: Must stop stem cell population from migrating into the myocyte 
population in order to produce a pure population of cultured myocytes. 
4.1.4 Establish Functions 
Based on the client and user interviews, the team developed a list of functions that 
the design must accomplish: 
• Must isolate at least 5000 living cardiac myocytes from a heart tissue sample 
• Must be able to maintain viable myocytes in culture for two weeks 
• Must be able to co-culture stem cells with cardiac myocytes to increase the 
presence of cell cycle markers in the cardiac myocytes over myocytes that are 
not cultured using this system 
• Must be able to prevent the stem cells from migrating into the myocyte population 
• Must include an analysis process that can prove that the cell cycle markers are 
being increased 
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4.2 Revised Problem Statement 
Based on the completed weighted objectives tree, as well as the lists of user 
requirements, constraints, and functions, the following revised problem statement was 
developed: 
Design a system or method that can be used to increase in the presence of cell 
cycle markers in adult mouse cardiac myocytes through a co-culture system with human 
mesenchymal stem cells.  The design must provide a distance of at least 200 µm 
between the cell types and keep the population of myocytes at least 90% pure. The 
isolation and culturing process should be able to take place inside a biosafety cabinet 
and the culture system must be able to fit inside an incubator.  The process must 
contain an analysis procedure that can give proof of the increase in cell cycle markers. 
4.3 Conceptual Design 
The revised problem statement allows the team to brainstorm and develop 
conceptual designs.  The purpose of creating a set of conceptual designs is to develop 
a set of ideas that can be analyzed for their strengths and weaknesses.  Once the ideas 
are analyzed, a design that is suitable for our particular application can be determined.  
There were two areas of the project that needed design alternatives, the cell isolation 
and the cell culture design. First, alternatives were generated and assessed for the cell 
isolation procedure using design matrices.  Then, a functions-means tree was 
generated to aid the brainstorming for the cell culture design, after which the design 
alternatives were generated and assessed using design matrices. 
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4.3.1 Design Matrices for Cell Isolation 
 The first step in creating a conceptual design is to brainstorm for ideas about how 
to accomplish our goals and aims while fulfilling our objectives.  The team generated 
three areas that needed to be addressed for the cardiac myocyte isolation.  We needed 
to choose an animal model, the medium that will be used for cell culture, and the 
technique that will be used for the myocyte isolation from the animal heart.  
After brainstorming, the team identified 6 possible animal models: rat, mouse, 
human, goat, cow, or pig.  The rat and mouse would be bought alive from Charles River 
Laboratories, Inc. in Wilmington, Massachusetts.  They would be euthanized by the 
team and the hearts extracted.  The advantage to lab animals is that they are raised in a 
controlled environment, but the hearts are much smaller, and therefore, harder to 
handle. The large animal models, goat, cow, and pig, would not be purchased whole. 
The team would go to a slaughterhouse and purchase the heart.  This means that the 
heart would not be as fresh as the laboratory animals.  They also would have been 
pasture grown, which means that there will be more variations from animal to animal. 
However, their hearts would be easier to handle than the small animal models and the 
hearts would yield more experiments per heart.  The final animal model considered was 
the human, which has all of the advantages and disadvantages of the large animal 
models.  Human hearts, however, would not be taken whole from cadavers.  The tissue 
that the team would be able to obtain would be taken from the patients during heart 
procedures where the tissue is normally removed.  This means that the tissue would 
most likely be from old, diseased hearts.  On the other hand, humans are the end users 
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of this design, so using human tissue would mean that there would need to be less 
interspecies adaptation if the design is successful. 
The ranking system that was developed to quantitatively assess these 
advantages and disadvantages can be seen in Table 3.  These criteria were used to 
complete the design matrix, which can be seen in Table 4.   
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Table 3: Ranking Criteria for choosing the animal model 
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Table 4: Design Matrix including rankings for choosing the animal model 
 
Although the rat was the highest ranking animal model, the team chose to use 
the mouse instead. It was discovered that a graduate student, Christine Lima, was 
euthanizing mice on campus on a regular basis. She was willing to allow the team to 
have the hearts from her mice. This means that the team was able to acquire hearts for 
free leaving more money in the budget for other purposes.  Since the ranking of the 
mouse was only slightly below the ranking of the rat, the team felt that this was an 
acceptable choice.  
The brainstorming led the team to three possible choices for media to be used in 
the cell culture experiments: medium (Dulbecco’s Modified Eagle Medium, DMEM) + 
fetal bovine serum (FBS), conditioned medium from mesenchymal stem cells, and 
defined medium with proteins. The DMEM + FBS has been used in the past to culture 
hMSCs with cardiac myocytes (Doronin et al., submitted). The conditioned media 
experiment would be done by culturing the stem cells in a medium for a period of time, 
then aspirating that medium out of the culture dish and using it to culture the cardiac 
myocytes. This means that any products the stem cells secrete will be in the medium 
that is used for the myocytes. The defined medium with proteins would be the basic 
medium with specialized proteins added that are expressed during the myocyte cell 
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cycle. The hypothesis is that the cell cycle proteins would induce the myocytes to enter 
that phase of the cell cycle. An overview of these proteins can be seen in Appendix A: 
Cell Cycle Regulator Proteins.  
These attributes of the media types were quantified in the ranking chart seen as 
Table 5 and were used to assess the media types in the design matrix, included as 
Table 6.  
Table 5: Ranking Criteria for choosing the medium 
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Table 6: Design Matrix for choosing medium 
 
 
 
 The medium selected was the DMEM + FBS.  This is mostly due to the fact that 
this media has been shown to be effective in previous experiments (Doronin et al, 
submitted). Conditioned media may limit the amount of paracrine factors that can reach 
the cardiac myocytes if the paracrine factors have a short life span. The protein-
enhanced medium would have been carefully controlled by the team to ensure 
uniformity between experiments, but it would have been expensive to produce the 
amount needed for each experiment. 
The team established four methods that could be used to isolate the cardiac 
myocytes from the host tissue: trituration, scalpel, enzymes, and cell migration.  During 
trituration, small clumps of cells are pulled in and out of a pipette.  The shear forces in 
the pipette causes the cells to break apart.  This allows the tissue to be broken down 
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into individual cells, but would damage a percentage of the cells in the process.  The 
scalpel would be used to manually mince the tissue into small pieces.  This would not 
yield individual cells and would damage cells as well.  Enzymatic methods are 
commonly used in cell culture.  The tissue is placed into a bath of enzymes, typically 
collagenase, and the enzyme breaks the bonds between the cells.  This would yield 
individual cells without damage.  The cell migration technique involves putting the tissue 
into culture and allowing the cells to spread.  The spreading causes some of the cells to 
detach from the tissue.  Although this method would yield some individual cells with no 
damage, it would take a long time to obtain enough individual cells for our purposes. 
 The advantages and disadvantages of these isolation techniques were quantified 
in the ranking criteria chart, included as Table 7. These numerical ratings were used to 
complete the design matrix as seen in Table 8. The highest-ranking technique was the 
enzymatic process.  
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Table 7: Ranking Criteria for choosing method of cardiac myocyte isolation 
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Table 8: Design Matrix for choosing the method for myocyte isolation 
 
  
4.3.2 Design Matrix for Choosing Cell Culture System 
 The second part of the conceptual design process was brainstorming for possible 
means of cell culture.  From our initial research and our revised problem statement, we 
knew that we wanted to co-culture the myocytes with stem cells.  We needed to 
determine the type of co-culture we would want to do. There were four possibilities for 
co-culturing the two cell types: Transwell®, conditioned medium, random co-incubation 
with the mesenchymal stem cells (MSCs), and non-random co-incubation with the 
MSCs. The Transwell® and conditioned medium methods were described in Section 
2.4.1 Cell Culture.  The Transwell® system would keep the cell types separated, but the 
distance between the cell types is fairly large meaning that the paracrine factors 
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secreted by the stem cells may never reach the myocytes. The conditioned medium 
method would also keep the cell types apart, but the paracrine factors may denature 
before the medium is given to the myocyte population. The random co-incubation 
method would entail plating both cell populations in the same dish, making no attempt to 
keep the populations separated. This would decrease the distance between the cells 
and ensure that the myocytes would be exposed to the paracrine factors. The non-
random co-incubation would require the team to develop a new method of co-culturing 
cells that would keep the cell types apart, but reduce the distance between the cell 
types. The four methods were ranked according to the criteria listed in Table 9 and the 
results can be seen in Table 10. 
Table 9: Ranking criteria for choosing the cell culture system to be used. 
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Table 10: Design matrix for evaluating the four options for the cell culture system. 
 
 The non-random co-incubation with MSCs method was ranked the highest 
among the four possibilities. This means that the team would need to continue the 
design process in order to design a new method for co-culturing cells. 
4.3.3 Functions-Means 
 Since the cell culture system chosen required additional designing by the team, 
we needed to brainstorm for possible means of generating a non-random co-incubation 
culturing system. To aid with brainstorming, the team produced a functions-means tree 
as can be seen as Figure 8. In the figure, the square boxes represent functions and the 
ovals represent possible means. 
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Figure 8: Functions-Means Tree 
45 
 
 From the Functions-Means tree, two possible means of patterning the culture 
system were determined: a physical barrier or a chemical barrier.  A physical barrier 
system would entail generating some sort of material that could be placed between the 
cell types. In a chemical barrier system, some sort of chemical would need to be placed 
between the cell types to prevent the cells from migrating.  With this information in mind, 
the team was able to brainstorm for barrier options and developed Table 11, as can be 
seen below. These ideas are expanded in Section 4.3.4 Design Alternatives. 
Table 11: Brainstorming ideas for cell culture design 
Possible Methods for Patterning the Cell Culture 
Physical Barrier Chemical Barrier 
vertical cover slips PDMS stencil  protein patterning on surface 
agarose gel PDMS stamping on gold slides 
PDMS cloning rings  
 
 
4.3.4 Design Alternatives 
The team generated five design alternatives during the brainstorming session as 
can be seen in Table 11.  These five conceptual designs were further expanded by the 
team in an effort to understand the logistical issues behind these ideas. 
The first conceptual design that was discussed was the vertical cover slip design. 
In this setup, a rectangular glass slide would be used as the cell culture area.  Glass 
cover slips would be oriented vertically on the glass slide and held in place in order to 
form a barrier between the different sides of the slide, as can be seen in Figure 9.  The 
slide would be divided into multiple sections, like wells, allowing a different cell type to 
be cultured in each section.  The cells would then be put in their respective sections. 
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This would allow for alternating stem cell / myocyte culture sections.  The cover slips 
would be removed which would allow the cell types to freely share media. 
 
Figure 9: Conceptual design idea using vertical slides 
Another alternative involves using agarose gel to create physical barriers 
between the cell types, as seen in Figure 10.  The gel would be applied to the clean 
culture dish to create individual “wells” and allowed to set.  The cardiac myocytes and 
the stem cells would be pipetted into separate wells.  The agarose gel would act as a 
wall in between the two cell types.  The benefit of agarose gel is that it allows proteins to 
pass through the gel (Gutenwik, 2003).  This would have the benefits of a Transwell® 
experiment, with the media and proteins being shared between the cells, but the cells 
would be much closer together. 
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Figure 10: Conceptual design idea using agarose gel 
Another conceptual design utilizes the cloning cylinder, also known as the 
cloning ring, to produce a co-culture system.  The purpose of the cell cloning cylinder is 
to allow researchers to remove small colonies of cells that have grown in Petri dishes 
(McFarland, 2000).  Although they are effective for separating cells, the cloning rings 
must be used with sterile vacuum grease in order to contain the media and cells to one 
specific area.  The vacuum grease is not easily removed from the culture dish once it 
has been applied, so another method must be utilized for the design of this experiment.  
We propose using a ring made from polydimethyl siloxane (PDMS) to create a 
pseudo—cloning ring.  PDMS is a polymer that has been shown to create a seal with 
cell culture dishes (Folch, 2000).  The PDMS ring would allow for easy adherence to the 
culture dish without the addition of vacuum grease, while also allowing the cells to 
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remain separated by the barrier that the ring provides.  A sketch of this design idea can 
be seen in Figure 11 below. 
 
Figure 11: Conceptual design idea using cloning rings (traditional and PDMS) 
The fourth design alternative generated focuses on creating a stencil that can be 
adhered to the surface of the cell plate and then removed once the cells have adhered.  
The stencil would be made of PDMS, which will create a seal with the culture dish.  The 
stencil would be a wafer that is fitted to the bottom of the culture dish and a pattern 
could be cut out of it.  This pattern would create individual wells for the cell types, as 
seen in Figure 12.  The stem cells and cardiac myocytes would be plated in their 
respective wells.  The stencil would be made thick enough to prevent the media from 
entering neighboring wells. Then, after the cells have adhered to the surface, the PDMS 
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stencil would be removed.  It has been demonstrated that PDMS stencils can be 
removed without damaging the surrounding cells (Folch, 2000).   
 
Figure 12: Conceptual design idea using PDMS stencil 
 The final design alternative involves PDMS stamping on gold slides.  In a study 
by Heller et al., neural cells were patterned using PDMS microcontact printing on gold 
slides (Heller et al., 2004). We reasoned that a similar process could be used to pattern 
a gold slide for our co-culture system. The team spoke with Jonathan Charest, a student 
from Worcester Polytechnic Institute who spent the summer of 2007 developing a 
protocol for PDMS stamping on gold slides. We would need to design our own PDMS 
stamp, as can be seen in Figure 13.  The square parts would extrude from the surface, 
which is indicated by the darker region.  According to Jonathan’s protocol, the stamp is 
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coated with dodecanethiol and is pressed onto the slide and removed after 30 seconds. 
Then the slide is coated with (1-mercaptoundec-11-yl)tri(ethylene glycol) (EG3), which 
binds to the surface of the slide that is not coated in the dodecanethiol. The slide can 
then be coated with fibronectin, an extracellular matrix protein that is commonly used for 
cell adhesion (Ogawa, 2000).  The fibronectin only adheres to the dodecanethiol, so the 
result is a pattern similar to Figure 13 where the squares are coated with fibronectin and 
the darker regions are coated with EG3. The EG3 is extremely hydrophobic, so the cells 
will not migrate onto the EG3 and should stay in their individual regions. The cells could 
then be plated with myocytes on the top row and stem cells in the bottom region. 
 
Figure 13: Conceptual design idea for a PDMS stamp to be used on a gold slide.  
4.3.5 Design Matrix for Design Alternatives 
 To decide which of the design alternatives for the cell culture system the team 
would use, a design matrix was generated to evaluate the alternatives.  The alternatives 
were evaluated using the ranking criteria that can be found in Table 12. The agarose 
design was ranked the highest, as can be seen in Table 13. 
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Table 12: Ranking criteria for choosing the design alternative 
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Table 13: Design Matrix including rankings for choosing from the design alternatives 
 
4.4 Preliminary Design 
 The design for co-culturing cardiac myocytes with hMSC’s was a three-step 
process, as can be seen in Figure 14.  First, the team needed to isolate cardiac 
myocytes from an animal source.  Then the co-culture took place in a system that was 
designed by the team.  The final step involved analyzing the co-culture to determine if 
cell cycle markers were expressed by the myocytes. 
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Figure 14: Three-step process for the design 
4.4.1 Preliminary Cardiac Myocyte Isolation Procedure 
 The first step in our design was isolating the cardiac myocytes from the animal 
source. The design matrix for choosing the species (Table 4) resulted in using rats, 
however a graduate student at Worcester Polytechnic Institute, Christine Lima, was 
willing to donate mice for our use.  Since mouse was only slightly lower ranked than the 
rat in the design matrix and the donation would save money, the team determined that 
this would be acceptable.  The mice that were used were 2 to 3 month old female CF-1 
mice and were euthanized via CO2 asphyxiation.  Victoria Huntress, a biology staff 
member at Worcester Polytechnic Institute, showed the team how to extract the heart 
from the mouse.  The hearts were extracted from the mice within 10 minutes of their 
death.  The hearts were rinsed three times in a Tyrode’s solution.  The Tyrode’s solution 
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was made following the protocol provided in an article from the First Hospital of Xi ’an 
Jiaotong University (Wang et al., 2006). 
It was determined through the isolation design matrix (Table 8) that the cardiac 
myocyte isolations would be done using enzymes.  A protocol written by Joan 
Zuckerman from the State University of New York at Stony Brook that isolates myocytes 
from mouse hearts (see Appendix D: Mouse Myocyte Isolation Protocol) uses an 
enzyme called Blendzyme 4.  This was the enzyme that was chosen by the team.  We 
determined that in order to use the enzyme, the heart tissue would need to be broken 
down into small pieces to increase the surface area and there would need to be some 
physical agitation to help the enzyme to work the most efficiently.  We decided to use a 
scalpel to mince the tissue into small pieces and to triturate the tissue while it is in the 
Blendzyme solution.  Following the trituration, the solution was spun twice at 1000 
rotations per minute (rpms) and the pellet was resuspended in a KB solution after both 
spins.  The KB solution was generated by combining the protocols provided by the 
Wang et al. article and the protocol provided by Joan Zuckerman. 
Following the isolations, the myocytes were plated in KB for four hours.  The KB 
was then replaced with DMEM containing 1% penicillin-streptomycin. The media was 
replaced with DMEM containing 1% penicillin-streptomycin and 5% fetal bovine serum 
the following day. 
4.4.2 Preliminary Cell Culture Design 
 The second step of the design was the co-culture system developed to allow the 
myocytes to culture with HMSC’s.  The design matrix for choosing the design alternative 
indicated that our design should use agarose as a physical barrier between the cell 
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types.  The agarose was laid in a strip down the center of a cover slip using the process 
described below: 
 First, a PDMS mold was prepared by making a 10:1 mixture of silicone elastomer 
base: silicone elastomer curing agent.  This mixture was poured into a 35mm diameter 
Petri dish to a thickness of 3-5 mm.  The bubbles were removed by placing the dish into 
a vacuum for 20 minutes.  A 22x22 mm cover slip was placed vertically into the PDMS 
as can be seen in Figure 15.  The Petri dish was placed in a 60°C oven for 1 to 2 hours 
to cure the PDMS. 
 
Figure 15: The PDMS mold with vertical cover slip 
 
 After the PDMS cured, the cover slip was removed revealing a slit that went 
completely through the mold. The mold was then placed in a fresh Petri dish on top of a 
22x22mm cover slip.  The slit in the PDMS was lined up to exactly match the width of 
the cover slip as can be seen in Figure 16.  A 1% agarose in PBS solution was heated 
to 90°C and pipetted into the slit.  After the agarose set and gelled, the PDMS mold was 
removed.  This revealed a line of agarose down the center of the cover slip as can be 
seen in Figure 17. 
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Figure 16: The PDMS mold placed on top of a cover slip 
 
Figure 17: PDMS mold removed, leaving a line of agarose down center of cover slip 
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 This system allowed for myocytes to be plated on one side of the agarose line 
and HMSCs to be plated on the other.  We were able to vary the width of the line by 
adding multiple cover slips into the PDMS while it was setting.  In addition, after the 
culturing, the cover slip could be removed and analyzed on a slide.  In practicality, 
however, the line was not homogeneous.  The variation in widths along the line was 
noticeable with the naked eye.  Furthermore, the line never went all the way to the 
edges of the cover slip.  This means that the HMSC’s would have been able to migrate 
into the myocyte population.  This led us to our final design, which is described in 
Section 4.5.2 Final Cell Culture Design. 
4.4.3 Preliminary Analysis Procedure 
 The third portion of the design is the analysis procedure.  In order to show that 
the myocytes began expressing cell cycle markers, the team decided to stain the cells 
for a specific marker, Cyclin D1.  The myocytes also needed to be stained for α-actinin, 
and a Hoescht nuclear dye needed to be used to identify cell nuclei.  All of the myocytes 
were stained with the Hoescht nuclear dye, while half of those had the additional Cyclin 
D1 stain and the other half had the additional α-actinin stain.  After the staining 
procedure was complete, the myocytes were examined with a microscope and images 
were taken.  
4.5 Final Design 
 The trials with the preliminary design revealed the weaknesses of the design.  
The team reevaluated the processes used and developed the final design.  The final 
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design uses the same concepts as the preliminary, but it was able to fix the gaps that 
were discovered during the initial testing. 
4.5.1 Final Cardiac Myocyte Isolation Procedure 
 The preliminary isolation procedure was only modified slightly.  The procedure 
was adjusted so that the trituration would be completed using a water jacket at 37°C.  
This ensured that the Blendzyme would be more efficient than at room temperature.  
We added a second trituration to the procedure as well.  The first trituration would be 
done in the Tyrode’s solution containing Blendzyme. After the cell layer was removed to 
be spun, KB was added to the remaining tissue and the tissue was triturated again. The 
results from the Tyrode’s trituration were labeled H1 (H for heart) and the results from 
the KB trituration were labeled H2.  Also, many miscellaneous substances were in our 
end product, so the second spin cycle was decreased to half the speed (500 rpms) in an 
attempt to remove the unwanted material. The first spin cycle was maintained at the 
original speed (1000 rpms) to ensure that we did not lose any of the yield from the 
solution.  For details on the final procedure and the materials used, see the protocol in 
Section 5.4. 
4.5.2 Final Cell Culture Design 
 The preliminary cell culture design yielded an agarose barrier that was not 
uniform in thickness and did not reach the edges of the cover slip.  This meant that the 
hMSCs would be able to migrate around the barrier. A new method for laying down an 
agarose barrier was developed. Through experimentation, the team discovered that by 
using a micro-capillary pipette and depressing the plunger at a steady rate, an agarose 
 line could be laid down that was far more homogenous than using the PDMS mold 
approach.  The agarose was changed to a 2% solution.  The cover slip on the bottom of 
the Petri dish was still used to aid with the staining process.  The final design involv
using the micro-capillary pipette to lay down a line of agarose that completely bisected a 
22x22 mm cover slip on the bottom of a 35mm Petri dish. 
thickness of the agarose line was 
three different dishes. Each of the lines had a similar thickness which 
approximately 370 µm, which is above the 200 
be seen in Figure 18 below.  A cartoon and imag
Figure 19 and Figure 20, respectively
Figure 18: Agarose Barrier (scale bar = 400 microns)
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sufficient, we use bright field microscopy 
measured to be 
µm needed.  A representative image can 
e of the entire design can be seen in
.  
 
ed 
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Figure 19: Agarose Design Cartoon 
Figure 20: Agarose Design Image 
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In preparation for the myocyte isolations and the co-cultures, we prepared 
fourteen Petri dishes with agarose barriers. Ten dishes were plated with quantum-dot 
loaded hMSCs on one side of the barrier the day before the myocyte isolations, and two 
of those were set aside as the hMSC controls.  The hMSCs were quantum-dot loaded 
so that we would be able to distinguish between hMSCs and myocytes during the 
analysis procedure.  After the myocyte isolation, the remaining eight hMSC plated 
dishes had myocytes plated on the opposite side of the barrier, four from H1 and four 
from H2. The remaining four dishes that were not plated with hMSCs were plated with 
only myocytes, two from H1 and two from H2. These were used as the myocyte 
controls.  For details on the final procedure and the materials used, see the protocol in 
Sections 5.4 and 5.5. 
4.5.3 Final Analysis Procedure 
For the final analysis procedure, the team decided to stain for two different proteins. 
The first is cyclin D1, which is found in cells that have entered the cell cycle, indicating 
the potential for mitosis. The other protein, α-actinin, is found only in cells that are 
cardiac-derived. The purpose of using this stain is to show that the myocytes are still 
expressing a cardiac marker during the cell culture process. For details on the final 
procedure and the materials used, see the protocol in Section 5.6.2. 
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5. Methodology 
This section contains detailed descriptions of the methods used during the project. 
These methods include: cell culture, cardiac myocyte isolation, and making agarose 
barrier lines in plates/wells. Methods for analyzing data will also be discussed.  
5.1 Overview 
There were several important goals that were essential for the project to 
demonstrate the effectiveness of the design. First, it was essential that the team learn 
how to culture, passage, and feed cells using sterile techniques. Also, it was necessary 
to learn the process of isolating cardiac myocytes from fresh mouse hearts. The third 
goal was to be able to reproducibly create uniform agarose barriers on cover slips within 
culture dishes. Finally, it was important to develop an analysis method to demonstrate 
the effect of the co-culture on the different cell populations. The strategy for achieving 
each goal is described in the sections that follow. 
5.2 Maintenance of Cells in Culture 
The research performed as part of this project involved the use of human 
mesenchymal stem cells (Lonza Group Ltd.) as the cells to be co-cultured with mouse 
cardiac myocytes. In order to have a set of hMSCs ready to be used for the co-culture 
experiments, it was important to maintain a line of hMSCs in culture for the duration of 
the project. The following are protocols for feeding and passaging cells. The feeding 
protocol also contains a step regarding quantum dot loading in hMSCs, with the 
quantum dots being used to identify hMSCs in culture. 
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5.2.1 Feeding Cells 
Materials: 
• Media (Cellgro, DMEM 1X, Cat. # 10-013-CV) 
• Penicillin-Streptomycin Antibiotic Cocktail (Cellgro, Pennicillin-Streptomycin 
Solution, Cat. # 30-001-CI) 
• Fetal Bovine Serum (PAA Laboratories, FBS, Cat. # A15-201) 
• Sterile phosphate buffered saline (PBS, Cellgro, Cat. # 21-030-CM) 
• T-75 flask 
• Serological pipettes 
• Pipettor 
• Sterile glass Pasteur pipettes and aspirator 
• Quantum dots (QD655 ITK carboxyl quantum dots, Invitrogen, Cat # Q21321MP) 
 
Procedure: 
1. Place media and PBS in water bath to warm. 
2. Wearing gloves, place all materials in hood that will be needed for the procedure. 
3. Remove cells from incubator and place in biosafety cabinet 
4. Aspirate old media using Pasteur pipette 
5. Use pipettor to add 5ml sterile PBS to flask. Gently tilt the flask to expose the 
entire bottom to PBS. Aspirate PBS. 
6. Use pipettor to add 10 ml fresh media to the flask. Check the flask with the 
microscope to make sure cells look healthy.  
7. Place flask in incubator. Clean the biosafety cabinet with ethanol. 
8. In order to load quantum dots into hMSCs, it is necessary to feed the cells with 
medium containing quantum dots. For this, 10µl of QuantumDot 655 were added 
to 10 ml medium, and the medium was fed to the cells following the steps above. 
Medium was removed after 24 hours and replaced with fresh media. 
 
5.2.2 Passaging Cells 
 
Materials: 
• 5ml Trypsin aliquot (Cellgro, Trypsin 1X, Cat. # 25-050-CI)  
• Media 
• 15 ml conical tube 
• T-75 flask 
• Serological pipettes 
• Pipettor 
• Hemocytometer 
• Micropipettor and tips 
• Trypan blue 
 
Procedure: 
1. Place trypsin and media in water bath. 
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2. Remove the desired T-75 flask (with cells) from the incubator and place in cell 
culture hood. 
3. Place trypsin and media in cell culture hood. 
4. Aspirate off the media using a sterile glass Pasteur pipette. 
5. Using a pipette, remove 5ml of trypsin from aliquot and add to the T-75 flask. 
6. Place the T-75 back in the incubator for 5-10 minutes. Check the flask to make 
sure that the majority of cells have lifted. 
7. Add 5ml media to the flask. 
8. Using a pipette, remove the entire cell suspension and place in a new 15ml 
conical tube. 
9. Centrifuge the cells (be sure to use a counter balance). Centrifuge at 800 rpm for 
5 minutes. 
10. Aspirate the supernatant (media and trypsin) using a sterile glass Pasteur 
pipette. Be sure not to disturb the cell pellet. 
11. Re-suspend the cell pellet with a known amount of media (2ml). 
12. Remove 10µl of the cell suspension, combine in an eppendorf tube with 90µl of 
trypan blue stain (50 µl trypan blue + 40 µl PBS). 
13. Mix the cells / trypan blue well using the micropipette. 
14. Remove 10µl of the cells / trypan blue and place in the hemocytometer. 
15. Count the cells using the hemocytometer. 
Cells/ml = (#cells/#squares) x 10 (dilution) x 104   
16. Plate the cells with the desired concentration in a new T-75 flask. 
17. Add fresh media to the T-75 to achieve the desired final amount of media 
(usually about 10-15ml). 
18. Write necessary information on the new T-75 (cell type, passage number, date, 
initials, cell plating concentration), place in incubator. 
19. Dispose of the old T-75 flask in the biohazard bag. 
20. Place media back in refrigerator, clean the cell culture hood, turn on UV 
assuming no other experiments are in hood. 
 
5.3 Making the Agarose Barrier Line  
In order to effectively utilize the agarose, it was essential to first try making 
different concentrations of agarose in order to observe the concentration that would 
yield the best degree of firmness for the experiments. Figure 21 and Figure 22 show the 
process of making the agarose solution, and Figure 23 shows the process of making the 
agarose barrier using the microcapillary pipet. 
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Figure 23: Making Agarose Barrier 
Figure 21: Making Agarose Solution 
Figure 22: Warming Agarose 
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Agarose was poured into a round mold, allowed to set, and removed for observation. 
Agarose concentrations of 1%, 2%, 4%, 6%, 8%, and 10% were used. Images from 
these preliminary tests can be found in Appendix F: Making Agarose. The final 
concentration of 2% was chosen because it stays liquid long enough to work with easily, 
yet stays firm when formed into a mold or line. The protocol for making the agarose 
barriers on cover slips can be found below. 
Materials 
• Agarose-HGT (USB, cat. 32805) 
• PBS (Fluka Biochemika, Cat. # 79382) 
• Serological pipette 
• Microcapillary pipette (Stratagene, 10µl volume) 
• Pipetter 
• Hot plate 
• Thermometer 
• Tongs 
• 250mL beaker of water 
• Precision metric scale 
• Weighing paper 
• Spatula 
• 25mL beaker 
• Mold 
• Autoclavable bottle 
• Cell culture materials (well plate and/or petri dishes) 
• Biosafety cabinet 
 
1. Put beaker of water (at least 80% full) on the hot plate. Insert the thermometer 
and let the water heat to 90°C. 
2. Make a 2% agarose solution by combining 0.2g of agarose per 10ml PBS. Use 
the pipettor with the serological pipette to measure out the desired amount of 
PBS into the beaker. Weigh the amount of agarose needed and combine the 
agarose and PBS in the ependorf flask. Gently swirl the flask to mix the solution 
3. Use the tongs to hold the small beaker in the beaker of water. Swirl the flask 
occasionally and do not allow any water to get into the flask. You will know that 
the gel is ready when you can not see any particles remaining in the solution 
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(look directly down into the flask, looking from the side is inadequate). The gel 
should easily swirl and should be slightly clearer than the original mixture. 
4. Pour the agarose solution into an autoclavable bottle that is significantly larger 
than the volume of agarose. Autoclave the agarose using a liquid cycle. 
The following steps occur in the biosafety cabinet 
5. Reheat the agarose in the cell culture hood using a hot plate. Transfer a small 
amount of the agarose from the large bottle to a smaller container, such as a 
small beaker. 
6. Use a microcapillary pipet to draw up 10µl of agarose. Hold for 10 seconds to 
allow the agarose to gel.  
7. Expel the agarose gel slowly and continuously onto the glass cover slip in the 
Petri dish. Be sure to keep the line as uniform as possible until you reach the 
other side. Dispose of excess agaose left in microcapillary pipette. 
8. Using the microcapillary pipet, quickly draw up more agarose and quickly expel 
onto the ends of the agarose line you just created. This is done to ensure that the 
agarose meets the side of the dish, and provides a full barrier between the 
different cell types that will be plated. 
9. Make more wells/dishes as necessary for the experiments. 
10. Seed hMSCs on one side of the cover slip the day before cardiomyocyte 
isolation. Allow the cells to sit for 4-6 hours, then remove the media and replace 
with fresh (cell-free) media. Repeat again before cardiomyocytes are plated. This 
is to keep the hMSCs on one side of the dish/well. 
 
5.4 Cardiac Myocyte Isolation from CF-1 Mice 
The isolation of cardiac myocytes from adult mouse hearts is a detailed process 
involving a series of steps that can take several hours to complete from the time of 
obtaining the hearts until the cells are plated. Although the procedure is long, the 
cardiac myocytes can be isolated and plated on cell culture surfaces. The procedure 
involves the use of an enzyme called Liberase Blendzyme (Roche Diagnostics, Cat # 
11988468001). This enzyme contains collagenase and other enzymes in a specific 
blend used for tissue dissociation applications. The exact formulation is not published. 
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5.4.1 Making Tyrode’s and KB Solutions 
There are two solutions used during the cardiac myocyte isolation procedure. 
These solutions and others like them have been used in similar research with primary 
isolations (Wang et al., 2006). Their purpose is to keep the myocytes alive during the 
isolation and plating process and to allow for the cells to be gradually introduced into the 
cell culture environment.  
Tyrode’s solution is made by combining the ingredients listed below in the 
appropriate amounts. All ingredients are weighed and mixed with water. The solution is 
filtered into an autoclaved (sterile) bottle with a bottle top filter in a biosafety cabinet.  
Table 14: Tyrode's Solution Formula 
Tyrode's Solution molecular weight mM g/L g/500 mL g/250 ml 
NaCl 58.3 140 8.162 4.081 2.0405 
KCl 74.5 5.4 0.4023 0.20115 0.100575 
MgCl2 95.1 1.8 0.17118 0.08559 0.042795 
HEPES 238 10 2.38 1.19 0.595 
Glucose 180 10 1.8 0.9 0.45 
 
The KB solution involves a few more steps than the Tyrode’s solution. All of the 
necessary ingredients are listed in the table below. All ingredients in Table 15: KB 
Solution Formula(EXCEPT ATP) are added into a flask with the appropriate amount of 
water. The entire solution is mixed on a stir plate/hotplate, with the heat turned on. The 
solution must be watched so that the solution temperature does not rise above 37ºC. 
The ingredients will not dissolve without the combined stirring/heat. Once the solution is 
clear, it is filtered using a bottle top filter into an autoclaved (sterile) bottle while in the 
biosafety cabinet. On the day of the isolation, the appropriate amount of ATP should be 
added to a small amount of KB (only what will be used that day). The KB+ATP solution 
should then be filtered using a syringe filter. The ATP is not stable in the KB solution for 
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more than a few days, so the ATP should be added as close to the isolation as possible 
(morning of isolation). 
 
 
Table 15: KB Solution Formula 
KB Solution molecular weight mM g/L g/500 mL g/250 ml 
KCl 74.5 25 1.8625 0.93125 0.465625 
KH2PO4 136.1 10 1.361 0.6805 0.34025 
MgCl2 95.1 3 0.2853 0.14265 0.071325 
Glucose 180 10 1.8 0.9 0.45 
EGTA 380 0.5 0.19 0.095 0.0475 
Taurine 125 20 2.5 1.25 0.625 
L-glutamic acid 147 70 10.29 5.145 2.5725 
HEPES 238 10 2.38 1.19 0.595 
ATP 551.14 0.5 0.276 0.138 0.069 
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5.4.2 Setting Up 
 
Figure 24: Preparing to Receive the Mice 
 
 
Materials: 
• Biosafety cabinet 
• Water bath (consists of water pump and glass water jacket) 
• Pipettor and serological pipettes (10ml and 25ml) 
• Conical tubes (15ml and 50ml) 
• Petri dishes 
• Scapel (#10 blade) 
• Forceps 
• Micropipettors and tips  
• Tyrode’s solution, KB Solution 
• Oxygen tank, regulator, and tubing 
• Sterile syringe with syringe filters 
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Setting Up 
 
1. Oxygenate Tyrode’s solution in the biosafety cabinet using medical grade 
oxygen. Place sterile Tyrode’s solution bottle into the hood. Spray tubing with 
ethanol and wipe down, immediately place one end in the Tyrode’s solution. Turn 
on the oxygen flow, and allow the Tyrode’s solution to oxygenate for 7 minutes. 
Repeat with sterile KB solution. 
2. After oxygenation of Tyrode’s solution, fill 15 ml conical tubes with 7-8ml of 
Tyrode’s solution. Have 3 conical tubes per heart. Set aside another 35 ml of 
Tyrode’s for later use. 
3. After oxygenation of KB solution, remove 50-75 ml of KB and place in non-sterile 
bottle. Add ATP as necessary per volume of KB, mix. Sterilize the solution into 
new 50 ml conical tubes using a syringe and syringe filters. 
4. Spray the glass water jacket with ethanol, wipe down, and place in biosafety 
cabinet. Be sure that the pump (placed outside of the hood) is filled to an 
adequate level (the water should be no more than a few inches from the top).  
Tube 1 should be connected from the outflow nozzle on the pump to the upper 
nozzle on the water jacket and tube 2 should be connected from the bottom 
nozzle on the water jacket to the inflow nozzle on the pump. Turn on the pump 
and set to 37°C. 
5. Sterilize water using a syringe and syringe filter, placing water into inner bath of 
the water jacket. Fill the inner bath  to roughly ¾ of the total volume. 
6. Prepare the dissection area: fill three small beakers with DI water, ethanol, and 
PBS to clean tools between heart extractions.  Obtain scissors and forceps. 
Place paper wiper on table for dissection surface. Have one 15mL conical tube 
with 7mL of sterile Tyrode’s solution for each heart that will be extracted. 
7. Prepare the biosafety cabinet (everything sterile): Have each of the following per 
heart – 2 small Petri dishes with lids, 2 conical tubes with 7mL of Tyrode’s 
solution. Also, have scalpel, forceps, 20ml Tyrode’s solution per 4 hearts (in 50 
mL conical tube), pipettor, 25mL serological pipettes, 10ml serological pipettes, 
Pasteur pipettes for aspirating, waste bucket. 
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5.4.3 Extracting the Heart 
 
Figure 25: Extracting the Mouse Heart 
Materials 
• Mouse 
• Spray bottle of ethanol 
• Small beaker (50ml) of DI water 
• Small beaker (50ml)  of ethanol 
• Small beaker (50ml)  of PBS 
• Gloves 
• Mask 
• Scissors 
• Forceps 
• 15mL conical tube with 7mL of Tyrode’s solution (one per heart) 
 
1. Be sure to wear a mask and gloves for this procedure. A lab partner will also be 
useful to ensure that the conical tube does not stay open for longer than 
necessary (see step 7). This entire process should be done as quickly as 
possible without damaging the heart. 
2. Obtain a euthanized mouse and use the spray bottle of ethanol to spray the skin. 
3. Use the scissors to cut through the skin, moving from the abdominal cavity 
upwards to the neck. Peel the skin back to move it out of the way (remove pieces 
if necessary). 
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4. Use the scissors to cut through the sternum, removing pieces if necessary, to 
expose the heart. 
5. Gently grasp the apex with the forceps and lift it out of the chest cavity, being 
careful not to pull too hard. 
6. Cut the connective tissue surrounding the heart until it comes free. 
7. Have a lab partner open the conical tube of Tyrode’s solution, drop the heart into 
the tube, and quickly cap. After recapping, keep the tube inverted so that the 
heart will not sit in / become caught in the small end of the conical tube. 
8. If obtaining more hearts, clean the surgical tools by rinsing in the beakers of DI 
water, ethanol, and PBS in between mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.4 Dissociating the Tissue 
 
Materials 
• Scalpel 
• Forceps 
• Petri dishes 
• 10ml and 25 ml serological pipettes and pipettor 
• Tyrode’s solution 
• KB solution 
• Blendzyme (Liberase Blendzyme 4, Roche Diagnostics, Cat. # 11988468001) 
Figure 26: Retrieving the Heart 
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• 50 ml conical tube (empty) 
• 15 ml conical tube with Tyrode’s (2 per heart) 
• 15 ml conical tube (empty, 3) 
 
1. This procedure should be completed in a biosafety cabinet while wearing gloves. 
This should also be done as quickly as possible in order to obtain the best yield 
of viable cardiac myocytes. 
2. Set up two Petri dishes with the lids acting as dishes (should have 4 dishes total). 
Gently invert the conical tube containing the heart several times, then pour the 
contents into the first dish. Use the forceps to lightly squeeze the heart to expel 
blood.  
3. Transfer the heart into a 15mL conical tube containing 7mL of Tyrode’s solution 
and cap. Gently invert the tube several times and pour the contents into the 
second dish. 
4. Transfer the heart into a 15mL conical tube containing 7mL of Tyrode’s solution 
and cap. Gently invert the tube several times and pour the contents into the third 
dish. Use the scalpel to cut away the atria and other tissue above. Gently 
squeeze the ventricles to expel any remaining blood. 
5. Pour ~5mL of fresh Tyrodes into the last Petri dish. Transfer the ventricles into 
this fluid and mince the tissue. Repeat steps 2-5 for all hearts, mincing all 
ventricular tissue in one final dish. 
6. Mix the aliquot of Blendzyme (200 µl) with 20mL of Tyrode’s solution in a 50mL 
conical tube. Use the pipetter with a 25mL serological pipette to transfer the 
minced tissue and surrounding fluid into the Blendzyme solution. Triturate for 7 
minutes with the conical tube in the water jacket at 37°C. 
7. Allow the tissue to settle and transfer the liquid layer to a new 15mL conical tube 
(use more than one 15ml conical tube if necessary). Cap and label this tube H-1 
(H for heart, 1 for first trituration). Spin the conical tube(s) in the centrifuge at 
1000 rpm for 5 minutes. 
8. You should still have a 50mL conical tube containing the minced tissue in a small 
amount of fluid. Add 10mL of the KB solution and triturate for 7 minutes. Allow 
the tissue to settle and transfer the liquid layer to a new 15mL conical tube. Cap 
and label this tube H-2 (H for heart, 2 for second trituration). Spin the conical 
tube in the centrifuge at 1000 rpm for 5 minutes. 
9. From this point on H-1 and H-2 treated the same way. After spinning, there 
should be a pellet formed at the bottom of the conical tube. In the biosafety 
cabinet, aspirate the fluid layer without disturbing the pellet. Resuspend in 5mL of 
KB solution and spin again at 500 rpm for 5 minutes. 
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5.5 Plating hMSCs and Mouse Cardiac Myocytes in Co-culture 
The following (Figure 27) is a series of images following the step-by-step process for 
co-culturing cardiac myocytes and hMSCs together. This process involves advanced 
plating of the hMSCs the day before cardiomyocyte isolation. Each image is marked 
with an approximate hour, starting from the time of initial hMSC plating. Each image 
also shows the type of media that is used for each cell type at any given time. Starting 
at hour 20, there are two dishes, one for the co-culture, and one for the myocyte control 
experiment. The last image shows the control dish in which hMSCs are plated at hour 0 
and allowed to grow for the duration of the experiment with no cardiac myocytes added. 
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     hMSC 
 
       Cardiac myocytes with KB solution 
 
 
    Cardiac myocytes with DMEM + P/S, no FBS 
 
    Cardiac myocytes with DMEM + P/S + 5% FBS 
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Figure 27: Co-culture Plating Over Time 
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 In order to effectively plate the cells as describe above, it is essential to follow a 
specific procedure during the first two steps of the hMSC plating. When the hMSCs are 
plated initially (hour 0), the dish is placed flat on the culture surface. The cell suspension 
is then plated in a small dot on one half of the cover slip. It is essential that the media 
not spill over the barrier because doing so will allow the hMSCs to plate on both sides of 
the barrier. Optimal plating would involve the cell suspension covering the entire half of 
the cover slip, however this is nearly impossible as the media can very easily spill over 
the barrier if it is placed too close to the agarose. Once the dot of media (~200µl total) is 
plated, the dish is placed in the incubator. It is helpful to place the dishes on a small tray 
or other flat surface (such as the top of a well plate) for easy transport. 
 After four hours, the media must be changed for two reasons. First, the amount 
of media placed on the dish at hour 0 is not sufficient to keep the cells healthy for longer 
than a few hours. Second, removing the media also removes floating cells that have not 
plated successfully. By replacing the old media with fresh (cell-free) media, the chance 
of having un-attached cells is reduced. At this point, the dishes must be tilted slightly, 
and more media must be placed in the dish. The media is filled in the tilted dish until 
almost reaching the agarose barrier. Again, this media must not cross the barrier in 
order to reduce the chances of hMSCs being plated on the wrong side.  The top and 
bottom of 35mm cell culture dishes work well as a prop to hold up the tilted culture dish 
with the cells.  
 During the cardiac myocyte plating the next day, the dish is returned to a flat 
surface. The hMSCs receive fresh media once again, although in a dot similar to that 
which was plated at hour 0. The cardiac myocytes are also plated in a similar fashion 
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using a dot of KB/cell suspension. Although mixing of the KB and DMEM  + 1% P/S 
+10% FBS is discouraged, there is a chance that these solutions will mix during plating. 
This is not a significant problem as the only population that needs to remain pure is the 
myocytes. Once the cardiac myocytes have been stepped up to a DMEM + 1% P/S + 
5% FBS medium, the entire dish is filled with 2 ml of DMEM + 1% P/S + 5% FBS to 
cover the entire cell culture surface. 
5.6 Analysis of Co-culture 
In order to prove the effectiveness of the system, it was important to develop 
protocols for staining the cells. The first protocol below was used for staining cyclin D1 
to identify cells that were actively involved in the cell cycle. The second protocol was 
used to stain for α-actinin, a protein found in cardiac cells (Doronin et al., as submitted), 
to identify that the myocytes can retain their cardiac characteristics through the cell 
culture process.  
5.6.1 Fixing the Cells 
All cells were fixed in methanol for 10 minutes, rinsed with PBS for 10 minutes, and 
stored in PBS in the cold room / refrigerator until microscopy analysis took place. 
5.6.2 Immunocytochemistry 
In order to analyze the effectiveness of the co-culture, the cells were stained for 
cyclin D1 and α-actinin. Due to the difficult nature of using two different stains in the 
same dish, half of the dishes were stained for cyclin D1 to indicate cells in the cell cycle 
and the other half were stained for α-actinin to indicate that the primary isolation cells 
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are indeed cardiac myocytes. All cells were stained with Hoescht Nuclear Dye to 
indicate that the cells contain nuclei.  
5.6.2.1 Cyclin D1 Protocol 
The Gaudette lab had an existing protocol for cyclin D1 staining that was used as 
the basis for the following protocol. The first attempt at staining for cyclin D1 was not 
successful, as all of the cells fluoresced under the microscope. After repeated trial and 
error, and with the help of the advisers, we determined that a new secondary needed to 
be purchased that would match the primary better than the existing secondary 
antibodies available in the Gaudette lab. The control cells used for this stain were Swiss 
Mouse NIH 3T3-J2 fibroblasts (Lindberg and Badylak, 2001). These cells were readily 
available in the lab and undergo mitosis under normal cell culture conditions.  
Cyclin D1 Staining Protocol for Immunocytochemistry  
Note: This procedure is done using cells that have been fixed with methanol. If fixed 
with paraformaldehyde, the cells will need to be permeabilized using a Triton-X solution. 
 
Normal Goat Serum (Invitrogen, 01-6201) 
Dilute serum in PBS to obtain 10% solution for blocking 
 
Primary Antibody - Cyclin D1, IgG2b (Santa Cruz, SC-8396) 
Dilute in PBS to obtain 1:100 dilution 
 
Secondary Antibody – goat anti-mouse IgG2b AlexaFluor 488 (Invitrogen A21141) 
Dilute in PBS to obtain 1:100 dilution 
 
Hoescht 33342 Nuclear Dye 
Dilute in PBS to obtain 1:6000 dilution 
 
Procedure: 
1. Fix cells using 100% methanol (10 min) 
2. Rinse cover slips with PBS (10 min x 2) 
3. Block cells using 10% goat serum (30 min) 
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4. Rinse with PBS (5 min) 
5. Prepare parafilm for primary antibody application. Remove necessary length of 
parafilm from holder, do not remove paper backing. Mark parafilm with each 
cell/culture type for identification. Remove the paper backing, being careful NOT 
to touch the clean side (that which was covered by the backing). Place 50µl of 
primary antibody solution on the clean side of the parafilm.  
6. Gently remove cover slips from the Petri dish and place them face down on the 
drop of primary antibody on the parafilm. Repeat for all cover slips, placing them 
in the appropriately marked areas. Place a wet paper towel next to (but not 
touching) the parafilm strips to avoid evaporation. Cover the setup with a tray or 
box. Allow cover slips to incubate with 1º for 2 hours. 
7. Remove cover slips from parafilm, placing face up in their respective Petri 
dishes. Rinse with PBS (5 min). 
8. Repeat steps 5. and 6. for the secondary antibody. Be sure to keep the antibody 
and cover slips in the dark as much as possible from this point forward as the 
secondary antibody is light sensitive. Allow the cover slips to incubate with the 
secondary antibody for 1 hour. 
9. Remove cover slips from parafilm, placing face up in respective Petri dishes. 
Rinse with PBS (5 min). 
10. Aspirate PBS and apply Hoescht dye to the cover slip (2 min) 
11. Rinse with PBS (5 min x 2) 
12. Setup slides for mounting. Obtain as many slides as you have cover slips, mark 
each slide with pertinent information (cell type, stain, date) and apply 2 drops of 
aqueous mount onto each slide.  
13. Remove one slide from the Petri dish and carefully place face down on the 
aqueous mount drop on the slide. Repeat for all cover slips. 
14. Once the aqueous mount has had a chance to set, seal the slides using clear nail 
polish to outline the edge of the cover slip. Store the slides in a cool dark place 
(preferably a slide folder or slide box). 
 
5.6.2.2 α-actinin Protocol 
The staining protocol was very similar to the one used the in Gaudette lab for tissue 
sections, with only minor modifications made for use with cells on cover slips rather than 
tissue sections on slides. The control tissue used for this stain was canine heart tissue 
sections.  
α-actinin Staining Protocol for Immunocytochemistry (adapted from Gaudette lab) 
 
Blocking Buffer – 2% IgG-free bovine serum albumin (BSA) in PBS 
Wash Buffer – 0.5% IgG-free bovine serum albumin (BSA) in PBS 
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Permeabilization Buffer – 0.25% Triton X-100 in PBS 
 
Primary Antibody – Mouse monoclonal α-actinin, sarcomeric (Sigma A-7811) 
Dilute in PBS to obtain 1:100 dilution 
 
Secondary Antibody – goat anti-mouse IgG(H+L)  AlexaFluor 546 (Invitrogen A11003) 
Dilute in PBS to obtain 1:100 dilution 
 
Hoescht 33342 Nuclear Dye 
Dilute in PBS to obtain 1:6000 dilution 
 
Procedure: 
1. Fix cells using 100% methanol (10 min) 
2. Wash cover slips with wash buffer (5 min x 3) 
3. Permeabiliz with Triton X-100 (10 min) 
4. Wash with wash buffer (5 min x 3) 
5. Block cells using blocking serum (45 min) 
6. Wash with wash buffer (5 min x 3) 
7. Prepare parafilm for primary antibody application. Remove necessary length of 
parafilm from holder, do not remove paper backing. Mark parafilm with each 
cell/culture type for identification. Remove the paper backing, being careful NOT 
to touch the clean side (that which was covered by the backing). Place 50µl of 
primary antibody solution on the clean side of the parafilm.  
8. Gently remove cover slips from the Petri dish and place them face down on the 
drop of primary antibody on the parafilm. Repeat for all cover slips, placing them 
in the appropriately marked areas. Place a wet paper towel next to (but not 
touching) the parafilm strips to avoid evaporation. Cover the setup with a tray or 
box. Allow cover slips to incubate with 1º for 1 hour. 
9. Remove cover slips from parafilm, placing face up in their respective Petri 
dishes. Rinse with wash buffer (5 min x 3). 
10. Repeat steps 5. and 6. for the secondary antibody. Be sure to keep the antibody 
and cover slips in the dark as much as possible from this point forward as the 
secondary antibody is light sensitive. Allow the cover slips to incubate with the 
secondary antibody for 1 hour. 
11. Remove cover slips from parafilm, placing face up in respective Petri dishes. 
Rinse with wash buffer (5 min x 3). 
12. Wash with PBS (5 min x 3) 
13. Aspirate PBS and apply Hoescht dye to the cover slip (2 min) 
14. Rinse with PBS (5 min x 2) 
15. Setup slides for mounting. Obtain as many slides as you have cover slips, mark 
each slide with pertinent information (cell type, stain, date) and apply 2 drops of 
aqueous mount onto each slide.  
16. Remove one slide from the Petri dish and carefully place face down on the 
aqueous mount drop on the slide. Repeat for all cover slips. 
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17. Once the aqueous mount has had a chance to set, seal the slides using clear nail 
polish to outline the edge of the cover slip. Store the slides in a cool dark place 
(preferably a slide folder or slide box). 
5.6.3 Microscopy 
Microscope images were taken of the control dishes to analyze the effectiveness 
of the agarose barrier. These images were taken using a light microscope to observe 
the placement of the hMSCs with relation to the agarose barrier.   
Fluorescence microscopy was used to analyze the immunostaining for cyclinD1 
and α-actinin. Images were taken of each cover slip, as well as the control cells/tissue to 
observe the success of the staining and of the co-culture system. 
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6. Results 
The following section provides the results for the experiments that were tested. This 
includes results from the myocyte isolation, agarose as an effective barrier studies, and 
staining of both control and experimental cells. 
6.1 Myocyte Isolation 
The isolation of cardiac myocytes was completed successfully on several occasions. 
Using the first batch of Blendzyme that the team had purchased, we were able to obtain 
single myocytes from the mouse heart as seen in Figure 28. These myocytes still had 
some indication of striations. Unfortunately, the attempt of myocyte isolation proved 
ineffective once the group switched to a new batch of Blendzyme after the first batch 
was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Cardiac myocytes–arrows indicate cells with striations (Scale bar = 100 microns) 
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6.2 Control Data for Cell Migration 
The figures below show the results at day 10 for the migration control study. In 
Figure 29, the hMSC side of the cover slip is shown with the cells approaching the edge 
of the barrier, indicated by the black line in the figure. The agarose was mostly removed 
during the fixing process, as the methanol degraded the agarose. However, the 
placement of the line was determined through scanning the rest of the cover slip and 
placing it in the same position as on areas on the cover slip where the barrier still 
existed. The pictures were not taken at those locations because the mounting fluid had 
coated the top of the cover slip, lowering the quality of the images in those locations. 
The opposite side of the cover slip was scanned completely and no cells were found 
past the barrier. Figure 30 is a representative picture of the control side of the cover slip. 
 
 
Figure 29: hMSCs approaching the agarose barrier (Day 10) 
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Figure 30: Representative image of the control (no cells plated) side of the (Day 10) 
 
6.3 Staining Data 
This section discusses the results of the staining procedure developed. Results 
include images from cyclin D1 and the α-actinin control as well as experimental data. 
6.3.1 Cyclin D1 Control 
 
The following is a set of pictures taken of NIH 3T3-J2 fibroblasts stained for the cell 
cycle marker cyclin D1. Figure 31 indicates the cyclin D1 staining as noted by the 
concentrated fluorescent green (surrounded by red boxes). Figure 32 indicates the blue 
Hoescht nuclear stain. Figure 33 is the combination of the two images to show the 
correspondence between the nuclei and cell body. Comparisons between staining for 
+/- cyclin D1 primary antibody can be found in Appendix G: Cyclin D1 Stain: Positive vs. 
Negative Stain. Note that all three images are taken at the same magnification. 
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Figure 31: Cyclin D1 Stain (scale bar = 50 microns) 
Figure 32: Hoescht Nuclear Dye (scale bar = 50 microns) 
Figure 33: Overlay - Cyclin D1 and Hoescht (scale bar = 50 microns) 
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6.3.2 α-actinin Control 
The following is a set of pictures taken of canine heart tissue sections that were 
stained for α-actinin. Figure 34 shows the α-actinin stain while Figure 35 shows the 
Hoescht Nuclear dye.  Figure 36 shows the combination of the α-actinin and Hoescht 
stains. Figure 37 is a blow-up of the α-actinin stain to show the striations in the tissue. 
These striations indicate the stain of the α-actinin protein in the cardiac tissue. 
Comparisons of staining for +/- α-actinin primary antibody can be found in Appendix H: 
α-actinin Stain: Positive vs. Negative Stain. Figs. 34-36 are all the same magnification. 
 
 
 
 
 
 
 
 
 
 
Figure 34: α-actinin Stain (scale = 10 microns) 
Figure 35: Hoescht Nuclear Stain (scale = 50 microns) 
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Figure 36: Overlay - α-actinin and Hoescht (scale bar = 10 microns) 
Figure 37: Striations in Cardiac Tissue 
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6.3.3 Experimental Data 
The following pictures are from the experimental system. Both pictures are from 
the myocyte side of the co-culture system. The DAPI filter revealed no fluorescing 
nuclei. The line at the bottom of the picture represents the edge of the agarose. 
Figure 38 shows the myocyte control culture dish (myocytes alone) while Figure 39 
shows the myocyte/hMSC co-culture dish. Notice that there is no cell matter in the 
agarose barrier region. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Edge of agarose 
barrier (notice no 
cell material in 
agarose) 
Myocyte side  
of cover slip 
Figure 38: Myocyte Control Dish (scale = 50 microns) 
Figure 39: Myocyte - hMSC Co-culture Dish (scale = 50 microns) 
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7. Analysis and Discussion 
 
In this section, we will analyze the data that we obtained. We will discuss the control 
studies for migration and staining. The section also contains hypotheses related to the 
complications that arose during the testing of our system. 
7.1 Myocyte Isolation 
 
The project team had no prior experience working with primary tissue isolations. As 
such, Professor Gaudette and Joan Zuckerman (SUNY Stony Brook) were instrumental 
in answering questions and teaching the group how to effectively isolate cells from the 
mouse heart. This step was essential to the project as no co-culture experiments could 
have been performed without cardiac myocytes. Figure 28 shows an example of the 
myocytes that were isolated from mouse hearts. However, these particular cells were 
not able to be plated in the co-culture system as the final design was not yet developed.  
The first several attempts to isolate cardiac myocytes were a valuable learning 
experience for the team. First, it was imperative that the team learn how to open the 
mouse and retrieve the heart. Through trial and error we learned that the heart could be 
removed along with excess tissue (i.e. lungs) attached, and that the tissue could be 
more easily removed once the heart was removed from the body. We also discovered 
that the minced heart tissue would yield more cells if the initial pieces were as small as 
possible. By cutting the tissue into very small sections, each piece can be exposed to 
the Blendzyme solution, thereby allowing more surface area for the enzyme to work.  
Additionally, we learned that it was important to use a 25ml pipet for the trituration 
process as anything smaller will cause heart tissue to become lodged in the end of the 
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pipet. Finally, we believe that time is a factor in isolating healthy myocytes. The first two 
or three isolations took a long amount of time to complete (~6 hours) and there were 
very few healthy myocytes and the end of the procedure. After a few isolations, we were 
able to cut the time in half (~3 hours or less). While we were still using the first 
Blendzyme batch, the isolated myocytes were healthier and more single cells were 
isolated as the isolation time decreased.  
Once the team developed and implemented the final design using the agarose 
barrier, it was believed that myocyte / hMSC co-cultures would begin.  After the protocol 
had been developed and proved successful, the following isolations were yielding little 
to no myocytes.  However, the original batch of Blendzyme had been consumed by the 
experiments developing the cell isolation protocol and a new batch had to be 
purchased. Additionally, the hearts had to be transported from Gateway Park to 
Salisbury Labs, which added (roughly) an extra 30 minutes to the time between 
extraction of the heart and the start of the isolation process. The team believes that one 
or both of these changes in the process may have caused the myocyte isolation to yield 
little to no myocytes, thereby limiting the amount that could be used in the co-culture 
system.  
Although we were faced with these challenges, we were able to develop a 
successful protocol for isolating myocytes when the isolation is done under optimal 
conditions.  The protocol developed was far easier to complete than the original protocol 
the team attempted to use since it was less technically challenging. This protocol was 
proved successful at isolating single, healthy myocytes during several independent 
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isolation attempts. The healthy myocytes that are isolated using our protocol can be 
used in our co-culture system. 
 
7.2 Migration Control Assay 
 
The migration experiment was conducted in order to observe the migration of 
hMSCs up to agarose barrier, and to observe the hMSC behavior once the cells 
reached the barrier. The control migration study was conducted for 10 days. We plated 
2 dishes for each time point (1 day, 2 days, 5 days, and 10 days). All four time points 
indicated no migration past the barrier, and images were taken of the day 10 time point 
because it is the longest culture time. In addition, the hMSC control for each isolation 
were observed for hMSC migrations. As the co-cultures were not cultured longer than 7 
days, a 10 day migration assay was sufficient for the design to work effectively. By 
thoroughly scanning each dish and taking light microscope images, the team observed 
that the hMSCs did not grow past the agarose barrier at day 10. The cells did grow 
close to the barrier; however they did not grow through or over the agarose.  
As seen in Figure 29 in the results section, the hMSCs are confluent on the left side 
of the picture, and the cell density decreases as the cells move closer to the barrier. 
Based on observations of previous days, the cells had grown to the opposite edge of 
the cover slip (the one opposite the agarose barrier). Once the cells near the agarose 
reached the barrier, they did not grow directly up to the barrier.  The first explanation 
that the team considered was that the cells had just begun to migrate into the area close 
to the agarose meaning that the space was just beginning to be filled.  However, the 
region of confluent cells near the barrier ends abruptly, whereas during cell migration 
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there should be a region of cells at a lower density surrounding the confluent region.  
This region of lower density is seen surrounding the confluent region in all areas of the 
cover slip with the exception of the side parallel to the barrier.  This suggests that there 
may be a factor that the agarose is emitting that prevents the cells from growing directly 
next to the agarose. However, the cells do not seem to be adversely affected by this 
possible factor, as the cells all looked attached and healthy from the team’s observation. 
The migration experiments proved that our co-culture system can be used to culture 
discrete populations for at least up to ten days. The system was more than efficient for 
our experiments since we only needed to co-culture the cells for 7 days.  As mentioned, 
the agarose did not seem to have any negative effects on the hMSCs, since they were 
healthy and attached to the surface of the cover slip.  This suggests that the system is 
biocompatible, but further testing would need to be conducted to confirm that finding. 
Also, this co-culture system has a wider range of uses than simply myocyte / hMSC 
co-cultures; our system could be used to co-culture any two types of cells that need to 
remain separated.  This means that our co-culture system could effectively replace 
insert co-cultures in many applications.  Our system could be altered to meet the 
specific needs of other co-culture experiments since the agarose can be laid down in 
any conformation desired.  It could be used to generate complex patterns in culture 
dishes, and so our system would be useful for a wide range of experiments. 
7.3 Plating Cells in Wells and Dishes 
During the preliminary stages of the agarose testing, the team tried many 
different variations of cell plating before finding a method that worked well. First, the 
team tried to use a 24-well plate with the agarose barrier to plate cells. As the cells were 
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plated, we noticed that the media seemed to be attracted to the edge of the well. When 
the media was placed in the well it would quickly move toward the wall, and then follow 
the shape of the wall. The media would follow at least halfway around each well, 
proving ineffective for hMSC seeding as the cells were to remain on only one side of the 
barrier. 
 In an attempt to develop a better system, the team moved up to a larger well size 
and experimented with a 12-well plate. This was done with the hypothesis that a larger 
well would allow more surface area for the media to be plated on the bottom of the well, 
where it would hopefully stay. Although we were able to place media in the bottom of 
the wells, it was always pulled to the wall and around the well by the time the team went 
back to change the media. At this point the team had to move to a larger well. 
 Based on the problems with the 24-well and 12-well plate, the team decided to 
try 35mm cell culture dishes. The 35mm dishes worked better than the well plates as 
the media was able to sit in the middle of one half of the well without being pulled to the 
wall. This was very important for effective hMSC seeding. However, the team did use 
caution when plating the cells as the media can very easily spill over the agarose if it is 
placed to close to the barrier.  When great care was taken during plating and 
transferring, the plating process was successful at maintaining a pure population of 
myocytes. 
7.4 Staining 
The following is a discussion regarding the success of the staining protocols for 
control cells and tissue. There is also a discussion of possible reasons why the co-
culture staining was not successful.  
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7.4.1 Cyclin D1 Control 
The first attempt to stain control cells (fibroblasts) with cyclin D1 did not yield good 
results. Instead of seeing an effective stain that was localized in the nucleus, there was 
only general staining of all of the cells. After several more attempts with different 
combinations of primary and secondary antibodies, and with no effective stain found, it 
was necessary to look into other options. We now know that there are four isotypes of 
IgG antibody that are present in mice. The primary antibody we were using was specific 
to the IgG2b  isotype, while the secondary antibodies were for IgG2a, or for general IgG 
isotypes. This combination was not specific enough for the primary being used, so the 
team purchased a different secondary antibody. The new secondary, specific for IgG2b, 
worked well with the primary, providing the cyclin D1 staining that was present in the 
3T3-J2 fibroblasts. The success with this stain indicates the protocol as an effective 
method to indicate the presence of cell cycle markers in cells. 
7.4.2 α-actinin Control 
The first attempt to stain control tissue for α-actinin went very well, as the procedure 
had already been established by other people in the Gaudette lab. When the team tried 
to stain more control tissue with the α-actinin stain, it worked once again without any 
problems. This result was expected, and welcomed by the team. The success with this 
stain shows the ability to stain cultured cells with α-actinin as an effective method to 
show the presence of cardiac markers in cells.   
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7.4.3 Experimental Data 
One of the goals for the team at the beginning of this project was to promote the 
expression of cell cycle markers in adult cardiac myocytes. Unfortunately, this goal was 
not accomplished, mainly because the cells that were plated in the co-culture system 
did not attach particularly well to the culture surface. 
 In regards to the attachment of the cardiac myocytes, there are several possible 
explanations. As described previously, there may not have been a population of 
myocytes plated in the first place for the co-culture experiments due to the reduced 
effectiveness of the isolation procedure. This may have been due to the movement of 
hearts between buildings, the new batch of Blendzyme, or both. Also, it is important to 
consider the culture surface of the system. The cover slips used were not tissue culture 
treated, nor were they covered with any coatings or substrates. A protein coating of 
laminin or fibronectin may have enhanced the attachment of any available cardiac 
myocytes. Although tissue culture treated Petri dishes may have been more effective, 
the amount of antibody necessary to stain an entire dish would have been much more 
than that which is needed for cover slip staining.  As mentioned in the design chapter, 
there were fourteen dishes that were plated during each experiment.  It is not feasible to 
stain fourteen entire dishes for each experiment, so cover slips needed to be used in 
order to allow for proper staining to occur without using an excess of materials. 
The attachment of the hMSCs may have been affected by several different factors. 
First, the hMSCs were at a high passage number (mid twenties). This could affect the 
attachment and proliferation of the hMSCs in culture. Also, the co-culture system used 
DMEM with only 5% fetal bovine serum in order to provide an acceptable environment 
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for cardiac myocyte culture. The team observed the hMSCs beginning to ball up in this 
media, and tried to remedy the situation. We tried to add DMEM + 8% FBS, however 
this proved to be ineffective. It is possible that the hMSCs were already too damaged to 
be brought back to a healthy state, or the late passage may not tolerate the lower 
amounts of FBS as well as an earlier passage. In any case, the hMSCs that were 
present in the co-culture were not healthy upon fixing, and therefore not well adhered to 
the cell culture surface. The team believes that this caused the hMSCs to wash off of 
the slide during fixing and/or staining procedures.  
Although we were unsuccessful in gathering quantitative data from the co-culture 
system, we have demonstrated that the system has the potential for success. As seen 
in Figures 38 and 39, the top portion of the pictures shows that there is myocyte cell 
matter in the field of view. Although the Hoescht dye did not indicate the presence of 
nuclei, the fact that there is something on the dish after multiple media changes 
indicates that at least some cell matter can be found in the system. Also, the line at the 
bottom of the pictures is the edge of the agarose barrier. If cells were moving through 
the barrier, then the cells / cell matter would be present in the barrier. Because there is 
nothing visible in the barrier, this indicates that the system is effective in keeping the cell 
populations separate from each other, which was the specific goal of this project.  
Although we were never able to conduct a successful experiment from beginning to 
end, we were successful at completing each individual component of the design during 
different phases of the design process.  We were able to isolate healthy myocytes which 
could be used for co-culture.  We were able to prove that hMSCs would not cross over 
the barrier and migrate into the myocyte population during the 7 day culturing period.  
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We were able to develop protocols for analysis of our system that would yield tangible 
results in a successful co-culture.  Since the individual components of the system work, 
it is reasonable to believe that the overall system would work.  We believe that had our 
successful trials of the individual components all occurred during the same experiment, 
the system would have yielded positive results.   
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8. Conclusions 
 
The project team has developed a system that allows for co-culture of two different 
cell populations. This system utilizes an agarose barrier that is effective against cell 
migration, while still allowing media to flow between the two different cell populations. 
This system allows for cells to be in closer contact than other systems previously used 
in co-culture research, allowing for cells to be less than 1mm away from each other, 
while still keeping the populations separate. The length and height of the agarose 
barrier can be altered for different applications, and the system itself could be used for 
other cell populations in the future.  This system could be used in any scenario where 
Transwell® systems are currently used, while allowing the co-cultured cells to be closer 
to one another and allowing the user to analyze the effects of distance between the cell 
types.  The team has also successfully developed a protocol for primary adult cardiac 
myocyte isolation, as well as staining procedures for cell cycle markers and cardiac 
tissue labeling. All of these results indicate that this system may one day be used for the 
co-culture of cardiac myocytes and human mesenchymal stem cells with the goal of 
promoting mitosis in cardiac myocytes for the treatment of myocardial infarction. 
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9. Future Recommendations 
The project team believes that this design has great potential for use in the future as 
a system to promote mitosis in adult cardiac myocytes. The improvements 
recommended here are for both short term and long term consideration.  
First, a reasonable short term recommendation is to reduce the size of the design to 
a smaller well size, perhaps a 12-well or 24-well plate. This would maximize the amount 
of space being used for co-culture. As the size of the design is decreased, the number 
of cells that can be co-cultured in close proximity (i.e. those that are close to the 
agarose barrier) can be increased. This may lead to a more efficient system for 
promoting cardiac myocytes to re-enter the cell cycle. 
The team also recommends that the media formulation be re-evaluated from two 
directions. First, it would be imperative to find a medium / serum formulation that allows 
for the effective culture of cardiac myocytes and human mesenchymal stem cells. This 
may involve using different serum levels, or using only low passage hMSCs. Also, it 
may be possible to add other components to the media, such as proteins, that may help 
to induce myocyte proliferation.  
Another recommendation includes re-evaluating the cell culture surface. The 
addition of a protein coating such as fibronectin or laminin may improve cell adhesion, 
thereby increasing the likelihood of cells being present on the slides for staining and 
microscopy.  
The final recommendation for improvements over a short time span would be to 
identify paracrine factors that are secreted by the hMSCs to promote myocyte 
proliferation. If these factors can be identified and developed into a therapeutic form, it 
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may be possible to treat MI directly. This could be done by administering these 
paracrine factors to an MI patient to directly stimulate the existing myocytes to 
proliferate and regenerate the damaged myocardium. 
 The long-term goal of this type of research is to induce human adult cardiac 
myocytes to proliferate. If this research can be proven effective using human cells, then 
it may be used as an effective treatment for MI patients. This could be done by 
stimulating the myocytes to undergo mitosis in vitro, and then placing the cells back in 
the infracted region. The development of an effective treatment for regenerating 
damaged myocardium would enhance the lives of millions of people affected by 
myocardial infarction, and research can only help in the search for answers. 
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Appendix 
Appendix A: Cell Cycle Regulator Proteins 
 
Table 16: Cell Cycle Regulator Proteins 
Group ame Type Phase Function Expression 
Cyclin 
Cyc A Mediator 
S, G2, 
M 
Partners with Cdk2 
Fetal and 
Neonatal 
Cyc B Mediator G2, M Partners with Cdc2 
Fetal and 
Neonatal 
Cyc D1 Mediator G1, S 
Critical for ventricular 
development, Partners with Cdk4, 
Cdk6 
Fetal and 
Neonatal 
Cyc D2 Mediator G1, S 
Critical for ventricular 
development, Partners with Cdk4, 
Cdk6 
Fetal and 
Neonatal 
Cyc D3 Mediator G1, S 
Critical for ventricular 
development, Partners with Cdk4, 
Cdk6 
Fetal and 
Neonatal 
Cyc E Mediator G1, S Partners with Cdk2 
Fetal and 
Neonatal 
Cyclin D-
dependent 
Kinases 
Cdc2 Mediator G2, M Aids mitotic phase initiation 
Fetal and 
Neonatal 
Cdk2 Mediator G1, S Phosphorylates Rb family 
Fetal and 
Neonatal 
Cdk4 Mediator G1, S Phosphorylates Rb family 
Fetal and 
Neonatal 
Cdk6 Mediator G1, S Phosphorylates Rb family 
Fetal and 
Neonatal 
Proteins 
p16 Inhibitor G1, S Impede Cdk4, Cdk6 activity unknown 
p18 Inhibitor G1, S Impede Cdk4, Cdk6 activity 
Fetal and 
Neonatal 
p21 Inhibitor G1, S Impede Cdk2, Cdk4, Cdk6 activity 
Fetal, 
Neonatal, 
Adult 
p27 Inhibitor G1, S Impede Cdk2, Cdk4, Cdk6 activity 
Fetal, 
Neonatal, 
Adult 
p38 Inhibitor  Induces differentiation  
p53 Inhibitor all Regulates cell cycle checkpoint unknown 
p57 Inhibitor G1, S Impede Cdk2, Cdk4, Cdk6 activity Fetal 
p193 Inhibitor G1, S Regulates G1/S checkpoint 
Fetal and 
Neonatal 
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Information for chart from Source (Ahuja et al, 2007) 
 
  
Pocket 
Proteins 
 Rb Inhibitor G1, S 
Critical for cell cycle exit and 
cardiac muscle differentiation, 
Impede E2F activity 
Neonatal 
and Adult 
p107 Inhibitor G1, S Impede E2F activity 
Fetal and 
Neonatal 
p130 Inhibitor G1, S Impede E2F activity 
Fetal, 
Neonatal, 
Adult 
TSC TSC2 Inhibitor G1, S Regulates p27 
Fetal, 
Neonatal, 
Adult 
E2F 
E2F1  
Transcription 
factor 
all 
Activator, expressed in 
proliferating cells, interact with Rb 
Fetal and 
Neonatal 
E2F2 
Transcription 
factor 
 
Activator, expressed in 
proliferating cells, interact with Rb 
Fetal and 
Neonatal 
E2F3 
Transcription 
factor 
all 
Activator,  expressed in 
proliferating cells, interact with Rb 
Fetal and 
Neonatal 
E2F4 
Transcription 
factor 
 
Repressor, expressed during 
differentiation, interact with 
pocket proteins 
Fetal, 
Neonatal, 
Adult 
E2F5 
Transcription 
factor 
 
Repressor, expressed during 
differentiation, interact with p130 
Neonatal 
and Adult 
E2F6 
Transcription 
factor 
G1, S Repressor 
Fetal and 
Neonatal 
E2F7 
Transcription 
factor 
 Repressor   
E2F8 
Transcription 
factor 
 Repressor   
Myc 
c-Myc  
Transcription 
factor 
all 
Critical for cardiac myocyte 
division 
Fetal and 
Neonatal 
L-Myc 
Transcription 
factor 
 
Critical for cardiac myocyte 
division 
 
N-Myc 
Transcription 
factor 
all 
Critical for cardiac myocyte 
division 
Fetal and 
Neonatal 
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Appendix B: Interview with the Client and the User 
Interview with Professor Gaudette and Jacques Guyette  October 5, 2007 
 
1. What would you like our project to accomplish? 
We would like to increase the presence of cell cycle markers within myocytes    
  
2. How would you be using this apparatus/procedure in your own research?   
The apparatus/procedure would be used to isolate cells and grow them in culture 
with a method to allow myocytes to proliferate 
 
3. How important is it to keep the cells sterile (for your purposes)? 
Have to be sterile^is a constraint 
   
4. Is cost an issue?  
Cost is not a significant issue. 
  
5. How long would you like the culture process to take?   
We would prefer a maximum culture time of 30 days from isolation to 
proliferation, but two weeks is more realistic. 
  
6. Is lab space an issue (can we take up as much space as necessary, or are we 
limited)?    
Lab space is not an issue, but culture space is. The system must fit within the 
incubator and cell culture hood. 
  
7. Have you noticed any specific problems in the past with this type of procedure?   
Contamination is always an issue during cell culture.  
  
8. Do you have a cutoff for the efficiency of the process (ie. 40% must express 
markers) or is it more about the number of cells?   
There is no specific cutoff, but the efficiency should be somewhere between 5% 
and 10%.   
  
9. What equipment/materials are available?   
Cell culture lab in Salisbury Labs which consist of an incubator and cell culture 
hood. 
 
10. How often would it be used? 
If the system works it will be used often. 
 
11. Would they working alone or on a team? 
Plan to have this be a one-person procedure. 
 
12. How many viable end product cells would be necessary to make the investment  
worthwhile? 
1 million cells would be the goal, finding cell factors 
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Interview with Professor Pins      October 4, 2007 
 
1. What would you like our project to accomplish? 
Design a bioreactor or cell culture system to enhance the efficiency of cardiac 
myocyte proliferation.    
  
2. How would you be using this apparatus/procedure in your own research?   
I would use these cells to engineer scaffolds and tissues to promote myocardial 
regeneration. 
 
3. How important is it to keep the cells sterile (for your purposes)? 
This is essential as non-sterile cells are useless! 
  
4. Is cost an issue?  
Always, the cheaper the better. 
  
5. How long would you like the culture process to take?   
As little time as possible.  Ultimately, cell culture time directly correlates with 
patient survival probability.  
  
6. Is lab space an issue (can we take up as much space as necessary, or are we 
limited)?    
Space is limited.  Unless you build a bench-top bioreactor that precisely monitors 
temp, pH, and humidity, you are limited to a device that will fit into a bio-safety 
cabinet and a TC incubator.  
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Appendix C: Pairwise Comparison Charts 
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C
o
lu
m
n
 
T
o
ta
ls
: 
15 100 100 
 
Express Cell Cycle Markers 
R
e
p
e
a
ta
b
le
 
E
ff
e
ct
iv
e
 
T
o
ta
l 
T
o
ta
l +
 1
 
P
e
rc
e
n
t 
o
f 
O
b
je
ct
iv
e
 
P
e
rc
e
n
t 
O
v
e
ra
ll 
Repeatable   0 0 1 33 11 
Effective 1   1 2 67 22 
   
C
o
lu
m
n
 
T
o
ta
ls
: 
3 100 33 
 
Safe 
F
o
r 
C
e
ll
s 
F
o
r 
U
se
rs
 
T
o
ta
l 
T
o
ta
l +
 1
 
P
e
rc
e
n
t 
o
f 
O
b
je
ct
iv
e
 
P
e
rc
e
n
t 
O
v
e
ra
ll 
For Cells   0 0 1 33 9 
For Users 1   1 2 67 18 
 
    
C
o
lu
m
n
 
T
o
ta
ls
: 
3 100 27 
 
 
 
 
 
112 
 
Ease of Use 
S
iz
e
 
T
im
e
 
In
te
rf
a
ce
 
S
im
p
li
ci
ty
 
T
o
ta
l 
T
o
ta
l +
 1
 
P
e
rc
e
n
t 
o
f 
O
b
je
ct
iv
e
 
P
e
rc
e
n
t 
O
v
e
ra
ll 
Size   1 0 0 1 2 20 1.4 
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Express Cell Cycle Markers 
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Appendix D: Mouse Myocyte Isolation Protocol 
Adult Mouse Myocyte Isolation 
 
  
Basic Solution(BS, Ca2+-free)  
       
Compound Concentration (mM) Amount (g/L) Amount (g/2L) 
NaCl 112 6.54 13.1 
KCl 5.4 0.40 0.8 
NaH2PO4  1.7 0.20 0.4 
MgCl2 1M  
Sigma M-1028 
1.63 1.63 ml 3.26 ml 
NaHCO3 4.2 0.35 0.7 
HEPES 20.04 4.78 9.56 
Glucose 5.4 0.97 1.94 
L-Glutamine1 
(200mM, Gibco Cat.no.25030-
081) 
4.1 20.5 ml 41 ml 
Taurine 10 1.25 2.5 
        
MEM Vitamins  
(Gibco, Cat.no. 11120-
052) 
100X 10 ml 20 ml 
MEM Aminoacids  
(Gibco, Cat.no. 11130-
051) 
50X 20 ml 40 ml 
 
pH 7.4 with NaOH, osmolarity should be ~ 292 mosm. 
Sterile filter (0.22 µm). Store at +4°C. 
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On the day of experiment, make solutions 
A. BS 50 ml+ 50ul heparin (Sigma H3393 dilute to 5000units/ml) 
B. Perfusion solution: BS 50 ml+BDM (2,3-Butanedione monoxime Sigma B0753) 
50 mg 
C. Plain BS bubbled with O2 (or 95/5 O2/CO2)- about 100ml for perfusion of tissue 
bath for cannulating aorta.  
D. Digestion solution: BS 50 ml + Blendzyme 4(Roche) 200ul of stock solution 
(Reconstitute 90mg vial as directed and aliquot 200ul/tube. Do not freeze and 
thaw.)  Add collagenase immediately before perfusion. 
E. KB+ ATP- bubble about 50 ml with O2. (Can be done while the heart is 
digesting). 
 
Procedure 
1 Rinse the isolation apparatus with filtered H2O before (and after) use. 
2 Bubble A with 100%O2. Pour B into a Langendorf syringe on the apparatus and 
bubble. 
3 Prepare to euthanize the mouse using 0.1ml of euthanasia pentobarb in a 1ml syringe 
with a 25 gauge needle. Set up three 60mm petri dishes with bubbled A and fill a 5cc 
syringe with A to use at the tissue bath. Place a small lump of clay on the edge of the 
tissue bath, fill the cannulation needle with A and wrap parafilm around the end so the 
needle does not empty. Place the needle in the clay with the end in the bath to 
cannulate the aorta.  
4 Euthanize the mouse by IP injection.  Pump C through the tissue bath. 
5 Open chest and remove the heart-thymus-lungs complex and rinse in the first dish. 
Cut away the lungs and rinse in the second dish.  Squeeze the heart very gently to 
expel blood. Transfer to the third dish. 
6. Place the heart in the tissue bath 
7 Pull away the fat residues from the distal part of aorta (cut again exactly below the 
branches if necessary) and cannulate it, tie it with 5-0 silk suture between heart and the 
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first branch, the tip could be seen via the aorta wall. Tie twice. Put the heart on the 5cc 
syringe and gently expel blood. 
8 Transfer the heart to the Langendorf apparatus and perfuse with B for 10 minutes. 
During this time, prepare D and place in second Langendorf syringe and bubble.  
9 Perfuse with D for 6 minutes. Examine heart. If the heart has become lighter in color, 
perfuse for an additional minute. If not, perfuse for a maximum of 3 more minutes.  
10 Remove the heart from the Langendorf apparatus and perfuse with KB in a 5 cc 
syringe (about 3 ml). Place the heart a petri dish of KB and cut away the atria with 
scissors, cut the ventricles into small pieces. Transfer the pieces to a 15ml tube and 
gently pipet up and down with a Pasteur pipet for several minutes. Filter  the solution 
through 210 micron nylon mesh, let the cells settle in the frig for about 20 minutes and 
resuspend in fresh KB. 
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Appendix E: Making PDMS Molds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 40: Making PDMS/Cover slip Molds 
Figure 41: PDMS in the Oven 
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Appendix F: Making Agarose 
After allowing the agarose to cool in the mold (Figure 42), the agarose was 
placed in Petri dishes and housed in a cell incubator overnight. This was done to ensure 
that the concentration used would retain its shape when heated to 37°C, as it would be 
during cell culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 42: Preliminary Agarose Testing - Mold 
Figure 43: Agarose 1% and 2% 
Figure 44: Agarose 4% and 6% 
Figure 45: Agarose 8% and 10% 
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Appendix G: Cyclin D1 Stain: Positive vs. Negative Stain 
Positive for Cyclin D1    Negative for Cyclin D1 
Figure 46: Positive Cyclin D1 Figure 47: Negative Cyclin D1 
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Appendix H: α-actinin Stain: Positive vs. Negative Stain 
Positive for α-actinin    Negative for α-actinin 
Figure 48: Positive α-actinin 
Figure 49: Negative α-actinin 
